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Abstract 
Adductor and Abductor Spasmodic Dysphonia: 
A Comparison of Quality of Life Issues for Those Receiving Botox Treatment 
By 
Thomas Brent Hofmann 
Northcentral University, September 2008 
Spasmodic dysphonia (SD) is a chronic vocal condition that significantly affects 
physical, psychological, and social well being. The preponderance of studies has 
been with the adductor type. This survey study examined 258 participants to 
ascertain if there is a difference in quality of life between the multiple types, 
controlling for Botulinum Toxin treatment. Abductor types comprised 32.2%, 
adductor types comprised 51.2 %, and mixed types comprised 16.6% of the 
sample. An intriguing finding was that there was a significant difference in quality 
of life between all mixed types and adductor plus tremor and abductor plus 
tremor versus simple abductor and adductor spasmodic dysphonia combined (t = 
2.603, df= 142, p = 0.01). However, the quality of life perceived by a person with 
SD did not necessarily correspond to the observed effectiveness of Botox 
treatment in most other cases. 
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CHAPTER 1 
Introduction 
Statement of the Problem 
Spasmodic Dysphonia (SD) impairs the natural movement of the vocal 
chords, causing functional communication difficulties. While the effects of SD 
vary, the disease usually affects the following domains of life: "Multiple 
physiologic (voice quality, effort, voice dependability); personal (affective 
responses, changes in self-view, coping strategies); and social (physical 
environment, other people, participation in social roles)" (Baylor, Yorkston & 
Eadie, 2005, p. 395). Communication is a vital mechanism in all areas of human 
life, and the effects are felt in multiple domains and can have a profound effect 
on quality of life (QOL). 
There are two main types of SD, the adductor version (ADSD) and the 
abductor version (ABSD). ADSD creates a strained, strangled voice with pitch 
breaks, and ABSD creates a hoarse, breathy voice. Another type of SD mixes 
the two main types together (MixedSD). In addition, each of these three types 
can be accompanied by a vocal tremor (TR), which causes rhythmic changes in 
voice ranging from giving the voice a quavering quality in more mild forms to 
causing temporary stoppages of voice in more severe forms. The types with 
tremor are ADSD with tremor (ADSDTR)V ABSD with tremor (ABSDTR), and the 
mixed type with tremor (MixedSDTR). It will be convenient here to also indicate 
that ABSD with or without tremor (ABSD [TR]), ADSD with or without tremor 
(ADSD [TR]), and MixedSD with or without tremor (MixedSD [TR]) are terms that 
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will be in frequent use. One might also have a primary voice tremor alone, but 
this is considered a distinct condition separate from SD (Barkmeier & Case, 
2000). 
The same treatment of choice, injection of Botulinum Toxin (Botox) into 
the vocal chords, is used for all types of SD. Botox provides a temporary 
chemical denervation of the laryngeal nerves, blocking them from over 
stimulating the muscles involved with vocalization (Blitzer, Brinn & Stewart, 1998; 
Boutsen, Cannito, Taylor & Bender, 2002; Watts, Nye & Whurr, 2005). There is a 
large body of literature which supports the fact that Botox treatment significantly 
improves QOL for many persons with SD (AN et al., 2006; Benninger, Gardner & 
Grywalski, 2001; Bhattacharyya & Tarsi, 2001; Blitzer et al., 1998; Boutsen et al., 
2002; Courey et al., 2000; Futrovsky, 1992; Hogikyan, Wodchis, Spak & Kilney, 
2001; Langeveld, Luteijn, Rossum, Drost & Baatenburg de Jong, 2001; Liu et al., 
1998; Ludlow, Naunton, Sectary, Schulz & Hallet, 1988; Murry, Cannito & 
Woodson, 1994; Murry & Woodson, 1995; Rubin, Wodchis, Spak, Kilney & 
Hogikyan, 2004; Truong, Rontal, Rolnick, Arnold & Mistura, 1991; Watts et al., 
2005; Wingate et al., 2005). Therefore, it is not possible to compare QOL of 
persons with SD without first controlling for Botox treatment. 
The literature usually does not distinguish between the three types 
(ADSD, ABSD, and MixedSD) with regard to whether those types have an 
associated tremor. When discussing previous studies, of necessity, the terms 
ABSD (U), ADSD (U) and MixedSD (U) will be used, and will mean that it is 
unclear from the study if that type with tremor is included in that study's sample. 
ABSD v. ADSD/Quality of Life Issues 3 
However, due to the prevalence of an associated TR, it is assumed that most of 
the larger samples did include some subjects with TR in addition to a main type. 
Therefore, in discussion of the literature, the ABSD (U) and ADSD (U) types will 
most often be used. In discussion of this particular study, the types ABSD (TR) 
and ADSD (TR) will be used most frequently. However, it is still assumed that 
most of these studies did have persons with an associated TR in their sample. 
There is also a definite difference in the effectiveness of treatment 
between the two main ABSD (U) and ADSD (U) types (Blitzer et al., 1998; 
Boutsen et al., 2002). However, the corresponding difference in QOL between 
those who suffer from ABSD (TR) and those who suffer from ADSD (TR) who are 
receiving Botox injections has not been studied. A survey the membership of the 
National Spasmodic Dysphonia Association (NSDA) was conducted in order to 
study the difference in QOL between these types of SD after treatment with 
Botox. In a recent survey of this same NSDA sampling frame, 65% (n = 493) of '» 
the respondents were currently being treated with Botox (Feeley, 2008). The 
studies previously conducted which had larger sample sizes were retrospective 
in nature. Even with larger sample sizes, the number of patients with ABSD (U) 
was very small (Blitzer & Brin, 1991; Adler, Edwards & Bansberg, 1997; Murry et 
al., 1994; Tisch, Brake, Law, Cole & Darveniza, 2003). Because of this trend, 
researchers have mainly studied ADSD (U), which is the most prevalent form of 
SD. Using the NSDA membership as the sampling frame, a sample size large 
enough to study the types together exists. 
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Background and Significance of the Problem 
Normally, there is a long delay for persons with SD between onset of 
symptoms and proper diagnosis (Nakanishi, 2001). One survey found that 52.6% 
of respondents were diagnosed between one and eight years after the onset of 
symptoms (Feeley, 2008). Only 22.2% were diagnosed in the first year (Feeley). 
This phenomenon speaks to the fact that SD is not widely known, even among 
professionals. In addition, until the last 25 years or so, research surrounding the 
etiology of SD appeared to be on the wrong track. 
Early theories on SD had characterized it as caused by personality 
characteristics that led to a psychosomatic conversion disorder. However, 
research that is more recent appears to demonstrate that pre-morbid personality 
structure does not correlate with SD (Liu et al., 1998; Murry et al., 1994). In fact, 
SD is currently understood as a focal dystonia of mixed etiology, not as a 
•- psychological problem (Finitzo & Freeman, 1989). 
Several studies have demonstrated the effect of SD on QOL by using 
standardized QOL instruments, as well as by qualitative interviewing in at least 
one case (Ali et al., 2006; Baylor et al., 2005; Benninger et al., 2001; 
Bhattacharyya & Tarsi, 2001; Courey et al., 2000; Hogikyan et al., 2001; Rubin et 
al., 2004). The researchers generally agree that the functional communication 
problems caused by SD influence the physiologic, psychological, and social 
domains of life (Baylor et al., 2005; Hogikyan et al., 2001). The degree to which 
SD affects an individual's QOL is dependent on multiple variables and the 
complex systemic interactions between them. These variables exist in the 
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interaction of the physiological, psychological/emotional, and social domains of 
life (Baylor et al.). While Baylor et al. propose a novel and detailed model for 
understanding SD in this light, most of the previous work had been done using 
the construct of QOL as defined by a QOL quantitative scale. 
A key variable identified in the research that affects the success of 
treatment is whether the SD is identified as ADSD (U), which is easier to treat 
with Botox injections and responds to them with better results for a longer period 
than ABSD (U). Mixed SD (U) does not respond as well as ADSD (U) treatment 
either (Blitzeret al., 1998; Boutsen et al., 2002; Watts et al., 2005). 
Another key variable that positively affects QOL construct measures or 
individual physiological, psychological, or social measures in several studies is 
the treatment of the person with SD by Botox injection into the vocal chords. 
Injection with Botox is currently the treatment of choice for SD (Blitzer et al., 
1998; Boutsen et al., 2002). 
SD has not only troubling physiological ramifications, but also 
psychological/emotional and social ones as well. QOL is significantly affected by 
this focal dystonia (Baylor et al., 2005; Hogikyan et al., 2001). One example of 
the physical problems is the quite fatiguing physical effort sometimes required 
just to talk (Baylor et al.). As evidence of the psychological/emotional component, 
those persons with SD who have not been treated effectively show significant 
symptoms of psychological distress that effectively treated persons do not show 
(Liu et al., 1998). Social functioning can be severely affected as well. As one 
example, there can be significant negative effects on a person's career from SD, 
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leading to poorer performance or a need to change professions (Smith et al., 
1998). In a survey of 758 members of the National Spasmodic Dysphonia 
Association, more than one quarter indicated that they had changed careers 
because of SD (Feeley, 2008). 
Given the demonstrated issues outlined above, one important area of 
focus for further research should be to understanding how SD influences QOL 
differently for those with the main two types ABSD (TR) and ADSD (TR), when 
those persons are being treated with Botox. This effort should include work on 
key variables, as well as a focus of the individual differences of the effects of the 
condition. Because most studies to date have been conducted with smaller 
sample sizes in individual clinics, an effort should also be made to use larger 
sample sizes in order to increase the validity of the resulting data. This study, 
using a larger sample size, will attempt to identify any differences in QOL 
between ADSD (TR) and ABSD (TR) after Botox treatment. This finding 
potentially could lead to further research on the differences between the ABSD 
(TR) and ADSD (TR) types. Collection of other key variables will also be 
conducted so that ancillary post hoc testing can be done to further explain the 
study result. 
Further studies could hone in on one form of less effectively treated SD 
and attempt to tease out any significant physiological, psychological, or social 
influences of SD distinct to this sub-population. This data may present more 
refined forms of treatment for that type of SD. The use of QOL as a construct 
represents the psychological and social effects of health problems, and highlights 
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the contributions that the discipline of psychology needs to make in this medical 
field. This kind of effort could help as this field transitions from identifying 
psychological pathology as a causative agent to eventually using psychological 
knowledge to tease out the complex systemic interactions between physiologic, 
psychological, and social elements of the condition. 
The large sample base of the NSDA provided a more comprehensive SD 
population representing all current types of SD, of which most are currently being 
treated with Botox, than the smaller sample at one medical clinic. The majority of 
previous studies took place in the voice clinic, and therefore provided a small 
sample size, with the exception of studies using retrospective designs. 
One intriguing exception to the preponderance of Botox/improved QOL 
studies was research by Wingate et al. (2005). This study, contrary to the bulk of 
research, did not show a significant improvement in mean QOL scale scores 
after Botox treatment. The researchers studied patients over 65 years of age. 
Wingate et al. noted that of a small sample size of 11, three subjects had 
significant problems with post injection side effects. Wingate et al.'s study pointed 
out two key directions for future research. First, that sample sizes should be 
larger in order to provide more power to the result. This is especially true 
because Hogikyan, Wodchis, Terrel, Bradford, and Escalmado (2000) found that 
variance in a larger sample of the voice disorder population was within 
acceptable range using an F Test. Thus, the effect of confounding variables such 
as age and side effect can be minimized. 
ABSD v. ADSD/Quality of Life Issues 8 
Second, researchers can obtain additional data for further analysis with 
minimal additional respondent burden without compromising respondent 
confidentiality, as will be outlined in the methodology section. This could include, 
for example, age of onset of SD, and current age, both of which could be 
compared in future studies against QOL data. The comparison of the current 
study, however, was between the types of SD and QOL, while separating out 
those who have and have not been receiving treatment with Botox. In fact, the 
group not receiving Botox injection was compared to the group receiving injection 
in order to confirm that this survey sample corresponded with the past research. 
Research Questions/Hypotheses 
Previous research has measured QOL but has not separated out the 
types of SD alone and in combination in QOL studies. Researchers have noted 
specifically that Botox works best for ADSD (U), based upon clinical measures 
(Blitzer et ah, 1998; Boutsen et al., 2002). 
Researchers have consistently studied ADSD (U) by itself because of the 
much larger sample sizes and the assumption that ABSD (U) and ADSD (U) are 
not alike in their effects on the individual. The research questions of this study 
asked: 
Research Question 1: To what extent is there a difference in QOL as 
measured by the V-RQOL for ABSD (TR) and ADSD (TR) for those with Botox? 
After the result from research question 1 was determined in this study, it 
led to ancillary post-hoc investigation of other research questions. This was done 
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in order to better understand the results. This inductive investigation led, in 
sequence, to the additional six research questions listed below. 
Research Question 2: To what extent is there a difference in QOL as 
measured by the V-RQOL subscale scores of Physical Functioning or Social 
Emotional Functioning for ABSD (TR) and ADSD (TR) for those with Botox? 
Research Question 3: To what extent do the demographic characteristics 
(duration, age, side effect, severity, and gender) of the participants significantly 
predict the QOL as measured by the V-RQOL? 
Research Question 4: To what extent is there a difference in QOL as 
measured by the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR versus 
ABSD and ADSD? 
Research Question 5: To what extent is there a difference in QOL as 
measured by the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR versus 
ABSD and ADSD without Botox? 
Research Question 6: To what extent is there a difference in QOL as 
measured by the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR, compared 
to ABSD and ADSD with Botox? 
Research Question 7: To what extent is there a difference in QOL as 
measured by the V-RQOL between ABSD and ADSD with Botox? 
Based on research question 1, the hypothesis for this study is: 
H1: There is a statistically significant difference in QOL as measured by 
the V-RQOL for ABSD (TR) and ADSD (TR) for those with Botox. 
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HO: There is no statistically significant difference in QOL as measured by 
the V-RQOL for ABSD (TR) and ADSD (TR) for those with Botox. 
As indicated in the discussion above of research questions, six additional 
research questions were generated. Six additional hypotheses, based on the 
research questions, were constructed and tested after the initial hypothesis was 
tested. These hypotheses are: 
H2: There is a statistically significant difference in QOL as measured by 
the V-RQOL subscale scores of Physical Functioning or Social Emotional 
Functioning for ABSD (TR) and ADSD (TR) for those with Botox. 
HO: There is no statistically significant difference in QOL as measured by 
the V-RQOL subscale scores of Physical Functioning or Social Emotional 
Functioning for ABSD (TR) and ADSD (TR) for those with Botox. 
H3: The demographic characteristics (duration, age, side effect, severity, 
and gender) of the participants predict the QOL as measured by the V-RQOL to 
a statistical significance. 
HO: The demographic characteristics (duration, age, side effect, severity, 
and gender) of the participants do not predict the QOL as measured by the V-
RQOL to a statistical significance. 
H4: There is a statistically significant difference in QOL as measured by 
the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR versus ABSD and 
ADSD. 
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HO: There is not a statistically significant difference in QOL as measured 
by the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR versus ABSD and 
ADSD. 
H5: There is a statistically significant difference in QOL as measured by 
the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR versus ABSD and 
ADSD without Botox. 
HO: There is not a statistically significant difference in QOL as measured 
by the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR versus ABSD and 
ADSD without Botox. 
H6: There is a statistically significant difference in QOL as measured by 
the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR, compared to ABSD and 
ADSD with Botox. 
HO: There is not a statistically significant difference in QOL as measured 
by the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR, compared to ABSD 
and ADSD with Botox. 
H7: There is a statistically significant difference in QOL as measured by 
the V-RQOL for ABSD and ADSD with Botox. 
HO: There is not a statistically significant difference in QOL as measured 
by the V-RQOL for ABSD and ADSD with Botox. 
Thus, this study will attempt to answer the seven research questions 
noted above by testing the seven corresponding hypotheses generated from 
them. 
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Definition of Key Terms 
Abduction. An uncontrolled and irregular opening of the vocal chords 
characterized by phonatory breaks and excessive breathiness (Pearson & 
Sapienza, 2003). 
Abductor SD (ABSD). Characterized by vocal folds that are abnormally 
apart during vocalization, creating a hoarse, whispered voice (Blitzer et al., 1998; 
Boutsen et al., 2002; Watts et al., 2005). This type may also have an 
accompanying tremor. 
Adductor SD (ADSD). Characterized by vocal folds that press abnormally 
toward the midline, creating a strained, strangled voice with pitch breaks (Blitzer 
et al., 1998; Boutsen et al., 2002; Watts et al., 2005).This type may also have an 
accompanying tremor. 
Adductor spasms. A closing off of the glottis, creating effortful stained or 
strangled quality to the phonation (Pearson & Sapienza, 2003). 
Analysis of Variance (ANOVA). A statistical technique that analyzes 
variance between multiple factors to determine the significance of relationships 
between them. 
Benzodiazepines. A class of anti-anxiety agents that can be useful as an 
adjunct to Botox therapy because they may help prolong the effects of Botox by 
relaxing muscles used during hyper-functional behaviors. 
Botulinum Toxin Treatment (Botox). Currently the recognized treatment of 
choice for SD in the medical community. Botox works by blocking the ability of 
the relevant laryngeal nerves from over stimulating the muscles involved with 
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vocalization. This is called chemical dennervation (Blitzer et al., 1998; Boutsen et 
al., 2002; Watts et al., 2005). 
Cascade Model. A three-stage model of grief developed to provide a 
model for emotional processing for those with a chronic voice disorder (de Jong 
et al., 2003). 
Contraction and Co-contraction Reflex. Muscular adjustments that 
synchronize bodily movement. With SD, these become uncoordinated, creating 
the adductor or abductor spasms. 
Conversion Disorder. A psychological diagnosis in which unacceptable 
emotion and impulse is represented by physical dysfunction. Part of the definitive 
diagnosis of this disorder is medical testing that finds no physical dysfunction. 
Corticobullar Tract. A tract that runs from the cerebral cortex down to the 
medulla oblongata in the sub-cortex. This location is currently implicated as the 
center of the neurological etiology of SD. * 
Direct Voice Rehabilitation. A series of technique used by Morton Cooper, 
a speech therapist. While this technique is represented as a cure for SD, there is 
no scientific evidence to support it. 
Electromyography (EMG). The use of percutaneous needles to measure 
the movement of muscles at rest and in contraction, an important tool in 
assessing and treating dystonias. 
Encryption. A protected tunnel for internet communication between a 
computer and a website. This protection was essential to protect the privacy and; 
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confidentiality of respondents completing the proposed survey utilized by this 
study. 
Glottal Attack. A phenomenon where the speaker brings the vocal folds 
abruptly together to produce sound, making speech effortful (Voice Definitions, 
n.d.). 
Hoarse Voice. A voice created by irregular vocal fold vibration producing a 
raspy, harsh, or grating sound (Voice Definitions, n.d.). 
Hyperfunctional Behaviors. Compensating speech behaviors used in order 
to compensate for the laryngeal dysfunction. These behaviors can worsen 
speech after treatment with Botox, and the current practice is to address them 
with speech therapy, as the behaviors have become habitual. 
Idiopathic Focal Dystonia. A focused movement disorder in which muscles 
contract and spasm involuntarily (Soland, Bhatia, & Marsden, 1996). 
Laryngeal Massage. A specific technique developed for those with 
dysphonia which brings the voice box lower down in the throat by reducing 
muscle tension and repositioning the voice box. 
Mixed SD. This type consists of ABSD plus ADSD or ABSD plus ADSD 
with a tremor. 
Muscle Tension Dysphonia (MTD). The cause of dysphonia as a result of 
excessive muscular tension in the muscles that relate to the voice box (Voice 
Definitions, n.d.). 
Partial thyroarytenoid myectomy. A surgical procedure for SD in which key 
laryngeal muscle is shaved down to a smaller size. This prevents glottal attacks 
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during adduction. This surgery might eventually replace SLAD-R because of its 
theoretical ability to retrain the nervous system. 
Percutaneous electrical stimulation. Stimulation of the Vagus nerve using 
EMG technology to connect to the correct area to provide electrical stimulation, 
usually for treatment of epilepsy; however, the treatment also creates adductor 
spasms. 
Peer Support. Used extensively around the world by the National 
Spasmodic Dysphonia Organization to provide psychosocial support for those 
with SD and their families using local groups and online discussion. 
Pitch. A sound that indicates how high or low a person's voice sounds 
(Voice Definitions, n.d.). 
Primary Voice Tremor (TR). A quavering voice that can become so severe 
that it causes adductor voice stoppages. It can occur alone or in combination with 
other types of SD. 
Quality of Life (QOL). A construct that has been measured by a known 
Quality of Life Scale, such as the Voice Related Quality of Life Scale (Hogikyan & 
Sethuraman, 1999). The construct consists of measures of respondent 
satisfaction with the physical, psychological/emotional, and social/career 
domains of life. 
Reverse Phonation. A speech therapy technique that has demonstrated 
the ability to reduce adductor spasm. However, because it relies on vocalization 
on the in-breath, it is very difficult to learn. 
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Selective Dennervation-Reinnervation (SLAD-R) surgery. Developed by 
Berke et al. (1999) to minimize the chance of the return of symptoms with ADSD. 
Adductor branches of the recurrent laryngeal nerve are severed and then 
reattached to cranial nerves other than the Vagus nerve that do not connect to 
voice production. This is thought to prevent re-growth of the laryngeal nerve. 
Side effects. Additional effects of Botox treatment include hoarseness and 
difficulty swallowing. This hoarseness creates a temporary idiopathic vocal 
problem while treating the SD. 
Sircle Technique. A technique that relies on thorough assessment, 
autogenic imagery retraining, and follow-up for a carpal tunnel like condition. It is 
possible that this treatment might be generalized for use with other conditions 
such as muscle tension dysphonia or adjunct treatment for SD. 
Spasmodic Dysphonia (SD). A focal dystonia that causes physical 
difficulty in speech. The ramifications of this difficulty also extend to the 
psychological and social realms of life. 
Survey Monkey. A proprietary survey website that was used for the 
proposed study. Respondents clicked a link in an e-mail and respond to survey 
items. 
Vagus Nerve. A nerve that starts in the Medulla Oblongata (brain stem), 
extending down to the head, neck, and abdomen. The recurrent laryngeal nerve 
stems from the Vagus nerve, ultimately connecting to the laryngeal muscles that 
control the voice box (Bocchino & Tucker, 1978). 
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T-Test. A statistical test used to compare two sets of data to determine 
whether differences between the two sets of data are significant. 
VHI (Voice Handicap Index). A QOL scale for use with a voice disorder 
population. In terms of breadth of health measured, VHI was defined as 
measuring 3 of 5 domains (physical, mental and communication) (Franic, 
Bramlett & Bothe, 2005). 
V-RQOL (Voice Related Quality of Life Scale). A QOL scale designed 
specifically for use with a voice disorder population. V-ROQL measures three 
criteria (physical, mental/emotional and social) related to QOL (Franic et al., 
2005). 
Whisper. A sound that passes through the vocal folds but does not cause 
them to move. Many with SD can whisper without SD symptoms (Voice 
Definitions, n.d.). 
Chapter Summary 
Early theories on SD characterized it as caused by personality 
characteristics that led to a psychosomatic conversion disorder. However, 
research that is more recent appears to demonstrate that pre-morbid personality 
structure does not appear to correlate with SD (Liu et al., 1998). 
In light of this research, SD is understood as an Idiopathic Focal Dystonia. 
The studies attempting to uncover etiology show that it is mixed. According to 
Finitzo and Freeman (1989), 50% of SD occurrences evidence multi-focal cortical 
lesions. Twenty-five percent have mixed sub-cortical and cortical pathology. 
Seven percent have sub-cortical lesions. However, a full 16% show no evidence 
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of cortical or sub-cortical lesions. In addition, histological studies have failed to 
identify any abnormality in the laryngeal nerve consistently, although they are 
sometimes discovered (Pearson & Sapienza, 2003). These lesions in the 
laryngeal nerve are thought to affect the functioning of the nerve and its ability to 
coordinate speech (Ludlow, Schulz, Yamashita & Deleyiannis, 1995). 
The symptomatic outcome of SD is either ADSD, with a strained/strangled 
vocal quality, or ABSD, with a hoarse, breathy quality. MixedSD refers to the two 
symptom sets together. ABSD (TR), ADSD (TR), and MixedSD (TR), add a TR to 
the symptom set, producing a quavering voice in its mild form, but producing 
temporary voice stoppages in the more severe form (Blitzer et al., 1998). 
These vocal symptoms create problems over the full biopsychosocial 
spectrum of QOL. Three domains are essentially thought to be affected: 
physiological, personal, and social factors (Baylor et al., 2005). There is 
significant agreement as to the domains, although terminology might change , 
slightly. For example, the creators of the VHI quantify the effects of voice 
disorders using Physical, Emotional, and Functional subscales (Jacobson et al., 
1997). The creators of the V-RQOL Scale, also used to quantify the effects of 
voice disorders, use Physical Functioning and Social-Emotional subscales 
(Hogikyan et al., 2001). Thus, SD can have significant effects on one's QOL in 
terms of not only physical difficulty but also the functional aspects of social and 
professional life, as well as psychological and emotional effects on the person: 
The physical symptoms of effortful speech and fatigue with speaking 
associated with SD are well documented (Blitzer et al., 1998; Boutsen et al., 
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2002; Ludlow et al., 1988; Truong et al., 1991; Watts et al., 2005). Psychosocial 
effects of SD are also well documented. These symptoms include anxiety, 
depression, social rejection and withdrawal, and occupational difficulty 
(Benningeret al., 2001; Bhattacharyya & Tarsi, 2001; Courey et al., 2000; 
Hogikyan et al., 2001; Rubin et al., 2004;). Please see page four for a more 
complete discussion of symptoms. 
Currently, the treatment of choice for SD is Botox injection into the 
appropriate laryngeal muscle (Blitzer et al., 1998). However, this treatment is 
more effective with ADSD (U) than for ABSD (U) (Blitzer et al.; Boutsen et al., 
2002). To this point, there does not appear to be a study that specifically 
measures the QOL benefit difference of Botox treatment for ADSD (TR) versus 
ABSD (TR) patients, despite research that shows a difference in treatment effect 
on symptoms. 
Much is still unknown about this condition, its etiology, or its effective 
treatment. It is suspected that SD is a Central Nervous System disorder that 
affects the recurrent laryngeal nerve and therefore affects vocal production. 
Research has so far uncovered an idiopathic focal dystonia with a mixed 
neurological etiology for SD. A specific cure for the condition is unknown; 
therefore, treatment now focuses on symptom management. However, this 
treatment (Botox injection) has a variable and limited effectiveness. 
As discussed above, there is an opportunity to advance knowledge of how 
SD affects individuals across the biopsychosocial spectrum. There are significant 
differences in manifestation of SD itself, and how it affects all domains of life. 
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Therefore, it is important to study how these differences affect QOL for those with 
SD. The extent that differences exist would hopefully prompt further research into 
the specific differences, especially as they relate to development of an effective 
treatment plan for each individual. 
Clinical observation has noted a striking difference in the superior 
treatment of ADSD (U) with Botox over ABSD (U) treatment with Botox (Blitzer et 
al., 1998; Boutsen et al., 2002; Watts et al., 2005). Almost without exception, 
studies comparing treatment with Botox for ADSD (U) and ABSD (U) reveal that 
treatment for ADSD (U) is more effective. However, the comparison of the more 
comprehensive measure of QOL after Botox treatment between those with ADSD 
(TR) and ABSD (TR) has not yet been done. 
The next chapter will review the history of research more extensively to 
describe the attempts to discover the etiology, effects on QOL, and best 
treatment choices for SD. This review confirms the need to research ADSD (TR) 
and ABSD (TR) QOL differences at this time in the process of researching this 
condition. 
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CHAPTER 2 
Literature Review 
Overview 
This literature review presents the current state of research on SD and 
related topics, as well as the specific influence SD has on QOL for those with 
ADSD (U) as compared to those with ABSD (U). A review of the relevant 
literature will follow in order to demonstrate the current level of knowledge about 
SD, its etiology, treatment, and influence on the individual. Previous research 
strategies, and research direction, will be outlined in order to develop a rationale 
as to the next step to be taken in the treatment of SD. 
Historical Background 
Early theories characterized SD as caused by certain personality 
characteristics, which led to a psychosomatic conversion disorder (Bloch, 1965). 
This assumption is obvious because.of the correlation between the significantly 
higher DSM Axis 1 symptoms of SD patients than the average population 
(Gundel, Busch, Ceballos-Baumann & Seifert, 2007). Researchers initially 
suspected a pre-morbid personality structure that implied a conversion reaction 
as a causative agent to SD. Aronson, Brown, Litin, and Pearson (1968) found 
that 60% of a sample of 20 SD subjects had psychoneurotic symptoms by clinical 
evaluation. However, the authors raised a caution flag in terms of how to interpret 
this correlation between psychiatric diagnosis and SD. Another important finding 
in this study was that SD patients also scored considerably lower on MMPI 
Hysteria and Hypochondriasis scales than control patients scored. In addition, 
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Murry et al. (2004) have found that symptoms of distress return to normal after 
effective Botox treatment for those with SD. The psychological correlations for 
SD patients are most likely due to distress over a vocally debilitating condition, 
not pre-morbid functioning. In addition, the interviewing psychiatrists and the 
researchers might have shown a predisposition toward attitudinal bias toward 
those with voice disorders as other studies have indicated (Amarpreet & Rochet, 
2000; Blood, Mahan & Hyman, 1979). 
Cannito (1991) and Murry et al. (1994) both conducted studies on SD. 
Cannito contended that depression, trait anxiety, state anxiety, and somatic 
complaints constituted four affective variables that correlated significantly with 
SD subjects versus controls. However, Cannito conceded that it is unknown if 
these variables can be correlated on the basis of reaction to a chronic disorder. 
Upon further study, Cannito et al. (1995), found that (utilizing the same 
constructs) depression, trait anxiety, state anxiety, and somatic complaints were 
significantly reduced one week after Botox injection, and that this effect was 
maintained at two months after the Botox injection. 
The physiological symptoms of SD are psychologically and emotionally 
troubling (Cannito et al., 1995). When treated with Botox, positive vocal changes 
lead to positive psychological and social changes (Futrovsky, 1992; Langeveld, 
et al., 2001; Liu et al., 1998; Roy, Bless & Heisey, 2000). When considered in 
concert with the improvement in QOL scales noted earlier, the potential for 
reducing physiological, psychological, and social distress with proper treatment is 
clear. This potential also argues strongly against SD stemming from a conversion 
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disorder, as was once thought because of its discovery and naming by Traube in 
1871 as nervous hoarseness (Pearson & Sapienza, 2003). Recent research also 
appears to demonstrate that pre-morbid personality structure does not appear to 
correlate with SD (Aronson et al., 1968; Futrovsky; Liu et al.; Murry et al., 1994; 
Roy et al.). 
One difficulty has been that there is indeed an adductor type of dysphonia 
known as Muscle Tension Dysphonia (MTD), a functional voice disorder. Upon 
initial clinical presentation, there may be significant difficulty establishing a 
differential diagnosis between MTD and SD. However, the two can be 
distinguished by spectral analysis (Rees, Blalock, Kemp, Halum & Koufman, 
2007), evaluation of phonatory airflow (Higgins, Chait & Schulte, 1999), 
phoniscopic evaluation (Leonard & Kendall, 1999), electromyographic study 
(Blitzer, Lovelace, Brin, Fahn & Fink, 1985), manipulation of the larynx (Roy,: 
Ford & Bless, 1996) and by noting clear differences in the severity of difficulty the 
speaker has in comparing voiced sentences to voiceless consonant sentences 
and whispering (Bloch, Hirano & Gould, 1985; Mauszycki, Merrill, Gouse & 
Smith, 2007; Roark, Dowling, DeGroat, Watson & Schaefer, 1995). In addition, 
there may be difficulties that present in distinguishing between SD, MTD and a 
primary vocal TR. TR may be seen alone as a primary TR disorder or in 
combination with SD. When seen alone, primary vocal TR is considered a 
different condition than SD (Barkmeier et al., 2000). 
As it became clearer that SD was distinct from MTD and did not show 
specific evidence of a functional voice disorder, researchers turned to a 
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physiological cause to explain SD. Initial research focused on possible damage 
to the recurrent laryngeal nerve. There is significant logic to this research 
direction. The recurrent laryngeal nerve is a branch of the Vagus nerve, and it 
supplies motor function and sensation to the larynx. Indeed, stimulation of the 
Vagus nerve leads to adductor vocal spasms (Charous, Kempster, Manders & 
Ristanovic, 2001; Kersig, Dejonckere, Van der Aa & Buschman, 2002). However, 
while there is some evidence in some cases of damage to the recurrent laryngeal 
nerve (Bocchino & Tucker, 1978), the results were far from conclusive (Chhetri, 
Vinters, Blumin & Berke, 2003; Ravits, Aronson, DeSanto & Dyck, 1979). 
Research efforts turned to a focus on the cerebral cortex and sub-cortical 
areas. In Schaeffer's (1983) study, the brainstem was implicated in SD, with 
central nervous system impairment positively correlating with severity of vocal 
TR. Historically, similar to studies of the recurrent laryngeal nerve, studies of 
cortical and sub-cortical areas point to a mixed etiology. Evidence of brain injury 
is not always present (Aronson & Lagerlund, 1991). 
Inconsistent results were also found by Devous et al. (1990). Cortical 
dysfunction of subjects with SD was found with one of several measuring 
methods; however, eight of the subjects evidenced no cortical or sub-cortical 
dysfunction. In fact, Finitzo and Freeman (1989), reviewing research to that point, 
noted that for over 50% of subjects' isolated multifocal cortical lesions can be 
identified, especially in the left frontal temporal cortex, medial frontal cortex, and 
right posterior temporal/parietal cortex. Twenty-five percent of subject had mixed 
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sub-cortical and cortical pathology. Seven percent had sub-cortical lesions only. 
For 16%, no lesions at all were identified (Finitzo & Freeman). 
Due to the apparent involvement of the motor control systems in SD, 
much of the current speculation focuses on the sub-cortical area, especially the 
Basal Ganglia (Pearson & Sapienza, 2003). Oh, Park, Cho, Choi, and Jung 
(2004) speculated that one case of SD that had developed after use of Valproic 
Acid, (believed to function as a GABA transaminase inhibitor). The 
extrapyramidal symptoms of SD were thought to be a result of perturbations in 
Basal Ganglia neurotransmitters. In another case study of SD, researchers found 
damage to the Basal Ganglia area (Lee, Lee & Kim, 1998). In a study of blink 
reflex among persons with focal dystonias (including SD), increased interneuron 
excitability was found. Tolosa, Montserrat & Bayes (2004) theorized that this 
phenomenon stemmed from abnormal input, possibly from the Basal Ganglia. 
The other focal dystonias are thought to have similar etiology to SD. 
Berardelli et al. (1998) noted on their review of the literature that all evidence of 
analysis of symptomatic dystonia points to a disorder of the Cortical and Basal 
Ganglia function. Like SD, all dystonias are characterized by an overflow of EMG 
activity and co-contraction of inappropriate muscles (Berardelli). Reduced spinal 
chord and brainstem inhibition is common to many reflex studies (Tolosa et al., 
2004). In SD, as in other dystonias, there is a marked inability to inhibit 
inappropriate reflex activity. 
However, the attempt to locate the specific dysfunction in the Basal 
Ganglia is far from conclusive. Hirano et al. (2001) found reduced activity in the 
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supplemental motor area using brain-imaging technology. This added weight to a 
theory of problems occurring in the entire neural network involving the cortex and 
sub-cortex, as opposed to one or the other. Pearson and Sapienza (2003) 
conclude that at present, SD as a focal dystonia is a disorder of motor circuitry 
and neurotransmitter function rather than structural damage to the cortex or sub-
cortex regions. 
Historically, the search for the etiology started with the theory that SD 
manifested due to a psychological conversion disorder. Research, while showing 
a clear correlation between Axis I anxiety and depression disorders and SD, also 
showed that the psychological distress subsided with effective treatment. 
Researchers turned to physiological factors in an attempt to understand the 
causality of this condition. Research has led to mixed results, with some 
histological studies finding problems with the recurrent laryngeal nerve, and other 
studies finding some problems with cortical and sub-cortical structures of the 
brain and associated pathways. However, no consistent finding exists. 
History of Surgical Treatment 
Without an accurate understanding of etiology for this condition, 
successful efforts to treat the condition have focused on symptom reduction 
instead of cure. Medical intervention began to focus on surgical treatment as it 
became apparent that other methods were not providing relief from the condition. 
Dedo (1976) began the use of surgery to relieve SD symptoms. Up to that point, 
older paradigms of SD treatment using speech therapy, psychotherapy, 
hypnotherapy, and drug therapy had proven ineffective (Barton, 1979). The initial 
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procedure removed a section of the recurrent laryngeal nerve, which in effect 
paralyzed the vocal fold on that side. 
In a follow up study for patients treated from 1975 to 1982, 82% had no 
symptoms of spasticity (Dedo & Behlau, 1991). Aronson and DeSanto (1981) 
experienced a higher rate of failure with this procedure of 39%. Others attempted 
less radical forms of the surgery in which the nerve was crushed (Billar, Som & 
Lawson, 1979), or selective section of the recurrent laryngeal nerve was done, 
which provided a partial adductor paralysis (Carpenter, Snyder & Henley-Cohn, 
1981). These less extreme methods are significantly less effective over the 
intermediate term, with return of symptoms in most cases (Dedo & Izdebski, 
1983). 
However, the search continues for a more consistently effective surgical 
procedure. Isshiki, Tsuji, Yamamoto, and lizuka (2000) reported on a thyroplasty 
procedure, in which the cartilage of the larynx is altered to lessen the degree of 
vocal chord closure, but was only done with one patient, who was without 
symptoms at a little more than one year post-operative. An earlier but similar 
technique was reported as successful with 16 patients (Tucker, 1989). 
Current Surgical Procedures 
Emphasis has shifted to the use of Selective Innervation-Reinnervation 
(SLAD-R) surgery. The technique grew out of the discovery that after recurrent 
nerve surgery, symptoms often returned and in some cases, the nerve 
regenerated (Wilson, Oldring & Mueller, 1980). In the surgery, the recurrent 
laryngeal nerves are severed and then re-attached to a nerve not associated with 
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SD. The idea behind this is to prevent re-growth of the recurrent laryngeal nerve, 
and thus the return of SD symptoms. 
The SLAD-R technique was developed by Berke et al. (1999), who found 
in follow-up at a minimum of twelve months and a median of thirty-six months 
that only one of twenty-one patients had a return of symptoms. Allegretto, 
Morrison, Rummage, and Lau (2003), using the SLAD-R procedure, found that 5 
of 6 patients showed improvement to the point where no symptoms were noted. 
This SLAD-R procedure currently offers the most hope for a consistent post-
operative and long lasting result. 
Another surgical technique that may show future promise is partial 
thyroarytenoid myectomy. In this procedure, some of the vocal chord muscle is 
shaved in order to weaken the adductor closing during vocalization (Genack, 
Woo, Colton & Goyette, 1993). Koufman, Rees, Halum, and Blalock (2006). 
reported on the procedure with five patients, all of whom had obtained a s 
satisfactory voice. The promise inherent in this procedure is that the reduced 
muscle mass may re-signal, through the recurrent laryngeal nerve, for the motor 
functions of the brain to re-synchronize to the lower capability of the shaved 
muscle fiber, but this is highly theoretical (Dr. D. Vincent, personal 
communication, February 28, 2008). Another possible direction for myectomy 
surgeries proposed by Ramacle, Plouin-Gaudon, Lawson, and Abitbol (2004) 
involves the use of eletrocautery in the myectomy procedure. 
At this point, surgical procedures hold promise, but they are not 
considered the first treatment of choice for SD. Below, other non-surgical 
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approaches that have been attempted will be discussed. These alternative 
therapies are instructive as to what has been attempted, but they generally do 
not offer significant promise for relief of primary symptoms. 
Non-surgical Alternative Strategies 
As mentioned earlier, electrical stimulation of the Vagus nerve affects 
vocal production, creating adductor spasms (Charous et al., 2001; Kersig et al, 
2002; Zalvan et al., 2003). Friedman, Toriumi, Grybauskas, and Applebaum 
(1989) had previously used percutaneous electrical stimulation to the recurrent 
laryngeal nerve, a branch of the Vagus nerve. While the researchers noted 
positive results, they conducted no further follow-up. This particular technique 
has shown more recent promise with ABSD (U). This will be discussed in more 
length in the current findings section (Bidus, Giovana & Ludlow, 2000). 
Wood (1991) first reported on the use of acupuncture treatment for SD. 
This case study of a 46-year-old male with ADSD (U) was judged successful. 
Crevier-Buchman, Laccourreye, Papon, Nurit, and Brasnu (1997) also reported 
that one subject was noted to have significant clinical improvement in vocal 
symptoms six months after treatment. More extensive sample sizes and 
evaluation methods of voice using clinical evaluation and QOL scales would add 
weight to the results of these case studies. 
In a study of the use of acupuncture treatment for SD, ten patients with 
ADSD (U) showed a significant improvement in VHI score (a voice related QOL 
scale). However, clinical voice evaluation for these patients did not show the 
same effect, and Lee et al. (2003) therefore could not rule out placebo effect. 
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While a moderate correlation exists with the VHI in terms of patient self-
evaluation of severity of the voice disorder (r = 0.60), Franic et al. (2005) contend 
that "data are lacking regarding discriminant validity for VHI" (p. 310). It is 
possible that improvement might have been due to some other source than voice 
improvement. It would also be instructive, for example, to compare VHI scores 
with actual clinical voice evaluation, as done in the Lee et al. study, to compare 
convergent validity. Therefore, more research is needed with acupuncture 
treatments with SD. It may be interesting to evaluate QOL using the V-RQOL, 
which shows discriminant validity in comparison of voice disordered patients with 
normal voiced controls (Franic et al.). 
Roy et al. (1996) reported on the use of manual laryngeal tension 
reduction via massage and manipulation of the larynx. While the technique was 
helpful in diagnosing the difference between muscle tension dysphonia and SD, it 
did not improve the primary symptoms of SD to. a significant degree. However, 
the technique does effectively alter the posture of the larynx as well as the 
position of the vocal folds. In persons with MTD, this manipulation can change 
both articulatory and phonatory behavior for the better (Dromey, Nissen, Roy & 
Merrill, 2008). Continued exploration of this technique with SD patients post-
Botox injection may show promise in extending the Botox benefit by reducing 
muscle tension associated with compensatory behaviors, which are continued 
even after post-Botox injection laryngeal relaxation. 
Henschen and Burton (1978) reported on the use of biofeedback using 
EMG on the laryngeal muscles. The sample size was two. No treatment progress 
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was noted with the primary symptoms of SD. It is interesting to note that in 
contrast to these results, Maryn, De Bodt, and Van Cauwenberge (2006) found 
that in a literature review of studies on the use of biofeedback with all types of 
dysphonia (except SD), most showed success in improving vocal symptoms. 
Speech therapy techniques also do not show effectiveness in the 
treatment of SD on their own. Harrison, Davis, Troughear, and Winkworth (1992) 
discuss the use of inverse phonation, otherwise called reverse phonation, in 
which sounds are produced during inhalation. During this abduction of the vocal 
folds and activation of the muscles used for the inhale, spasmodic muscular 
activity is minimized. While some success is noted with this technique, it is a 
difficult one to master and thus not useful as a consistent technique. As will be 
mentioned later, current thought proposes a combination of pharmacological 
treatment and speech therapy in combination. 
Cooper (1980) contended that a form of speech therapy termed Direct 
Voice Rehabilitation, in contrast to traditional voice therapy that attempts to 
decrease hyperfunctional behaviors, would work by focusing on good vocal 
hygiene. Much like voice coaching, Direct Voice Rehabilitation attempts to assist 
the patient in finding their natural speaking pitch and range. In addition, the 
technique attempts to project the voice into the "mask", or the facial area, 
projecting energy away from the throat (Cooper, 1984). However, there is no 
comprehensive scholarly evidence that this technique is effective (Pearson & 
Sapienza, 2003). 
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Another attempt to relieve symptoms historically has been the use of 
pharmacologic therapy. Anticholinergenics, benzodiazepines, and baclofen have 
been tried, but no significant improvement in primary SD symptoms has been 
noted. These medications may be used as an adjunct to more effective treatment 
(NSDA, n.d.). One person with ADSD, for example, had extended voice in a 
desirable range by using a benzodiazepine when spasm symptoms first became 
noticeable (G. Smith, personal communication, 4/3/2008). 
Of the alternatives to pharmacological treatment with Botox and surgery, 
electrical stimulation shows some promise, possibly for ABSD (U), but more 
study is needed with larger sample sizes. Speech therapy has been shown to 
extend the benefit of Botox treatment. Other techniques also may hold promise 
as adjuncts to more effective treatment, but none stands on its own. 
Current Findings 
The current theory on the etiology of SD is that it is a "disruption of neural 
networks involving both cortex and sub-cortex" (Pearson & Sapienze, 2003, p. 
325). Most recently, Simonyan et al. (2008) reaffirmed this theory by the use of 
diffusion tensor imaging with 20 persons with SD and 20 controls, and then 
analyzing post-mortem tissue samples from one person with SD and three 
controls. The researcher noted an abnormality for those with SD in the area that 
communicates between the cerebral cortex and the medulla oblongata. They 
note that the corticobullar tract, which runs from the cerebral cortex down to the 
medulla oblongata (brain stem) and associated input and output structures, were 
implicated in the CNS disorder. The corticobullar tract runs through the genu of 
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the internal capsule. According to the authors, these brain changes could be 
linked to voluntary control of voice production. 
In a study of the demographics of SD that covered 168 patients with SD 
using first degree relatives as controls, the age range for SD was found to be 13 
to 71 years old, with an average age of 49 (Schweinfurth, Billate & Courey, 
2002). Edwards and Bansberg (1997) found a mean age of 60 for men and 64.6 
for women, in a sample of 270 clinic SD patients. According to Adler, Edwards, 
and Bansberg, the ration of females to males in their clinic was 3.8 to 1. Tisch et 
al., (2003) found in their Australian clinic that out of 169 patients, 62.1% of 
patients were female and 37.9% were male. The mean age at diagnosis was 56 
years old, with their range of 19 to 88 years, slightly older at the bottom and older 
at the top of the range found by Schweinfurth et al. Blitzer and Brin (1991), in a 
sample of 260 patients, found a female to male ratio of 1.4 to 1. Persons with SD 
tend to be older, and are predominately women. With focal dystonias imgeneral, 
this pattern does not hold. For example, while the ratio of women is higher with 
regard to spasmodic torticollis, the ratio of men is higher with regard to writer's 
cramp (Soland et al., 1996). 
Adler et al. (1997) had 241 patients with ADSD (U) and 29 with ABSD (U) 
in their clinic sample. Tisch et al. (2003) noted that 89% of patients had ADSD 
(U), with 1.8% having the ABSD (U) variety and 4.7% having a mixed diagnosis. 
Blitzer and Brin (1991) found that out of their 260 patients, 32 had ABSD (U). 
Schweinfurth et al. (2002) contend that there are no environmental or hereditary 
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patterns in their data linked to SD, including family history. Most theories point to 
an illness, physical or psychological trauma, alone or in some combination. 
The effect of SD on QOL has been demonstrated by several studies using 
standardized QOL instruments and by qualitative interviewing in at least one 
case. The researchers generally agree that the functional communication 
problems caused by SD influence the physiologic, psychological, and social 
domains of life (Baylor et al., 2005; Benninger et al., 2001; Bhattacharyya & 
Tarsi, 2001; Courey et al., 2000; Deary, Wilson, Carding & MacKenzie, 2003; 
Estella & Yiu, 2001; Hogikyan et al., 2001; Hogikyan & Sethuraman, 1999; Rubin 
et al., 2004; Wilson et al., 2004; Wingate et al., 2005). Perhaps this dynamic of 
physiologic, psychological, and emotional struggle before effective treatment with 
Botox led to the hypothesis of correlation of increased psychiatric symptoms and 
a certain pre-morbid personality structure with SD. 
Key SD Quality of Life Variables 
The degree to which SD affects an individual's QOL is dependent on 
multiple variables, and the complex systemic interactions between them (Baylor 
et al., 2005). The severity of SD, for example, is correlated with QOL (Gundel et 
al., 2007; Jones, Carding & Drinnan, 2006). As one example, not only can SD 
cause physical fatigue from efforts to speak throughout the day, but more severe 
SD can also affect a person's own sense of self and how others react to them 
(Amarpreet & Rochet, 2000; Blood et al., 1979). 
Another key variable that positively affects QOL measures or individual 
physiological, psychological, or social measures in several studies is the 
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treatment of the person with SD by Botox injection into the vocal chords (Ali et 
al., 2006; Benninger et al., 2001; Bhattacharyya & Tarsi, 2001; Blitzer et al., 
1998; Boutsen et al., 2002; Courey et al., 2000; Futrovsky,1992; Hogikyan et 
al.,,2001; Langeveld et al., 2001; Liuetal., 1998; Ludlow etal., 1988; Murryet 
al., 1994; Murry & Woodson, 1995; Rubin et al., 2004; Truong et al., 1991; Watts 
et al., 2005; Wingate et al., 2005). 
Holden, Yokes, Taylor, Till, and Crumley (2007) noted that the 
methodology of injection appears to be refining itself. Initial dosage appears to be 
lower than in previous years. A higher dosage can be connected to more side 
effects. In addition, Holden et al. note that a stable dosage is usually achieved by 
the third injection. Because of the variability of effect, dosage must be adjusted 
for each person until approximate optimal does is reached. 
Lundy, Liu, Casiano, and Xue, (1997) also reported on differing 
methodologies for injection, dependent on desired effect. Length of response is 
longer with injection to target both vocal chords, but Lundy et al. noted more 
hoarse and breathy side effects. In a sample of 13 patients, Wingate et al. (2005) 
found that 3 had this side effect to the point that it significantly affected their QOL 
scores on the VHI. However, injection into one vocal chord decreased time of 
optimum benefit and decreased the hoarse and breathy side effect (Lundy et al.). 
In addition, Koriwchak, Nettwrville, Snowden, Courey, and Ossoff (1996) found 
that if side effects were troubling, a unilateral rather than bilateral injection 
significantly decreased reports of hoarse, breathy side effect. 
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Most current scenarios for best practice center on a combination of Botox 
and speech therapy treatment, specifically to enhance the benefit of the Botox. 
Murry and Woodson (1995) found, with a sample of 17 subjects receiving Botox 
and speech therapy and 10 controls receiving only Botox, the satisfactory 
amount of time subjects needed before re-treatment almost doubled with use of 
speech therapy. Silverman, Shrivastav, and Sapienza (2006) confirmed that 
Botox and effective speech therapy led to a longer, more desirable voice over 
just Botox or Botox and sham therapy. More studies are needed to continue to 
understand this extension of benefit from speech therapy techniques specifically 
designed to increase the benefit of Botox. 
Another key variable identified in the research is whether the SD is 
identified as ADSD (TR) (in which vocal folds press abnormally toward the 
midline, creating a strained, strangled voice with pitch breaks), or ABSD (TR). 
This is a key variable due to a clear difference in treatment effectiveness with 
Botox. ADSD (U) is treated more effectively by the standard treatment of choice 
(Blitzer et al., 1998; Boutsen et al., 2002; Tisch et al., 2003; Watts et al., 2005). 
Age is also noted as a key variable in effective treatment (Tisch et al., 
2003). In addition, Wingate et al., (2005), in contrast to the preponderance of 
studies, did not note a significant positive change in QOL scores after injection 
with botulinum toxin. The 13 subjects were all over 65 years of age. Commenting 
on this distinction, the authors also caution that the small sample size and the 
side effects of botulinum toxin may have confounded the results. 
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As mentioned above, previous research has measured QOL, but has not 
separated out the types of SD alone and in combination in QOL studies. 
Researchers have noted specifically that Botox works best for ADSD (U) based 
upon clinical measures (Blitzer et al., 1998; Boutsen et al., 2002). If properly 
controlled for Botox treatment conditions, what is the difference in QOL, 
especially post-Botox, for ABSD (TR) patients as compared to ADSD (TR) 
patients? 
Medical practitioners currently use Botox treatment for all types of SD 
(Blitzer et al., 1998; Boutsen et al., 2002; Watts et al., 2005). Is QOL more 
improved for those with ADSD (TR) than the other types upon use of Botox? If 
so, are other adjunct therapies needed? Do researchers need to identify other 
methods for treating the types which might be demonstrated as having 
significantly lower QOL after standard treatment? One intriguing exception to the 
preponderance of Botox/improved QOL studies was study by Wingate et al. 
(2005). The researchers studied patients over 65 years of age. However, the 
authors identify that their small sample size (n = 13) may have skewed the data. 
Treatment with Botulinum Toxin Injection 
As mentioned earlier, laryngeal injection of Botox is the current treatment 
of choice for all types of SD, because patients most often rate their voice as 
improved after treatment, and clinician observation of voice confirms this 
perception (Blitzer et al., 1998; Boutsen et al., 2002; Watts et al., 2005). 
Researchers have also clarified that voice is improved using Botox more 
effectively with ADSD (U) than it is with ABSD (U) (Blitzer et al.; Boutsen et al.; 
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Tisch et al., 2003). If ADSD (U) symptoms are demonstrably improved in most 
cases, even in a double blind study (Truong et al., 1991), then why would there 
be continuing and significant concern about assessing the negative influence of 
ADSD, as well as ABSD? 
The side effects of Botox usually affect most patients to some degree, but 
can be considerable for some. Clinicians in one study considered a hoarse and 
breathy voice of two weeks duration or less an acceptable side effect 
(Beilamowicz, Stager, Badillo & Godlewski, 2002). While this is considered as 
optimal, some patients struggle with a breathy voice that reduces their 
satisfaction with the injections considerably. In one case, 3 of 13 subjects 
experienced this level of trouble (23%) (Wingate et al.,2005). Indeed, someone 
with a similar hoarse and breathy condition such as laryngitis might find their 
lifestyle affected with a two week bout of the illness. 
In addition, the researchers noted a benefit of three months (or more) as 
an acceptable standard (Beilamowicz et al., 2002; Ludlow et al., 1988). As of 
August 2007, Blue Cross-Blue Shield of Florida allows reimbursement if Botox 
injections are spaced at least four months apart. In addition, patients must often 
schedule the next injection not at their exact moment of need, but by availability 
of the physician due to the necessities of scheduling. Therefore, even under an 
ideal circumstance the average patient may expect up to two weeks of laryngitis-
like symptoms immediately after injection and perhaps a month of returning 
spasms before the next injection. 
Botulinum Toxin Treatment and Quality of Life Differences 
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Despite these problems, there is a clear benefit to use of Botox for SD, not 
only in voice improvement, but also in QOL as measured by various QOL scales 
(Benninger et al., 2001; Bhattacharyya & Tarsi, 2001; Courey et al., 2000; 
Hogikyan et al., 2001; Rubin et al., 2004). However, QOL researchers have 
either distinguished an ADSD (U) population as their sample, or have not 
differentiated SD by type in the literature. In addition, several types of QOL 
scales specific to voice disorders exist, and thus a choice must be made as to 
which instrument to use. Several instruments exist that measure voice related 
QOL. Franic et al. (2005) have provided thorough analysis of the main scales 
that are specific to QOL and voice disorders. The authors conclude that the VHI 
is the better instrument for individual-level clinical decisions, while the V-RQOL is 
better for group level decisions. A more detailed discussion of the strengths, 
weaknesses, and rationale for choice of survey instrument are provided in 
chapter 3. 
At this point it may be important to tie in the link between observable 
clinical measures of voice, and the use of voice related QOL scales. It is 
documented that voice improvement is greater for ADSD (U) than ABSD (U) with 
regard to observable clinical data. Blitzer et al. (1998), for example, found that 
with an overall sample of 900 in a retrospective analysis, ADSD (U) patients had 
a return to 90% of normal voice lasting an average of 15.1 weeks. ABSD (U) 
patients had an average improvement to 66.7% of normal voice with an average 
duration of 10.5 weeks. Given the previous discussion as to side effects and 
duration issues even in the ideal treatment group, how significant is this reduction 
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in vocal benefit between ABSD (U) and ADSD (U)? Despite the difference in 
effectiveness, the researchers conclude, "Botulinum toxin A injection of the 
laryngeal hyperfunctional muscles has been found over the past 12 years to be 
the treatment of choice to control the dystonic symptoms in most patients with 
spasmodic dysphonia" (p. 1435). However, no measure of the difference in QOL 
as a result of the unequal treatment success has appeared in the research 
literature. 
Is there a significant difference in the QOL between ADSD (TR) patients 
treated with Botox and ABSD (TR) patients treated with Botox? If so, alternative 
treatment options might need to be developed. As an example, a currently 
emerging surgical procedure, selective dennervation-reinnervation surgery, is 
showing significant promise for the treatment of ADSD (U) (Chhetri, Mendelsohn, 
Blumin & Berke, 2006). Are alternative treatments for ABSD (TR) also available? 
As one example, Bidus et al. (2000) used percutaneous electrical stimulation of 
the portion of the laryngeal nerve responsible for adductor vocal movement. Ten 
subjects with ABSD (U) were found to have significant improvement in voice 
symptoms. Is this because the stimulation of this nerve pathway consisting of the 
vagus nerve (and the recurrent laryngeal nerve branch) creates more active 
adductor movement (Chavous etal., 2001; Friedman etal., 1989; Kersigetal., 
2002)? 
Further Analysis of Components of Quality of Life 
The discipline of psychology can also continue to contribute to the ongoing 
research on SD. Clearly, QOL scales designed to assess the influence of voice 
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disorders evaluate a composite of physiological, psychological, and social 
factors, especially in the systemic interaction of these domains with functional 
impairment in communication (Franic et al., 2004; Hogikyan & Sethuraman, 
1999; Jacobson et al. 1997; Wilson et al., 2004). Clinical evaluations of SD 
patients using DSM criteria and standardized anxiety and depression scales 
have been applied to this population as well, breaking down the composite of 
QOL into discrete emotional and social categories. These studies, however, have 
considered only a fraction of the entire systemic interaction of QOL influences of 
SD. 
This documentation of improvement in psychological and social 
dimensions using psychometric instruments makes it clear that the physiological 
symptoms become psychologically and socially troubling, and when treated with 
Botox, positive vocal changes lead to psychological and social changes (Aronson 
et al., 1968; Futrovsky, 1992; Liu et al., 1998; Roy et al., 2000). When considered 
in concert with the improvement in QOL scales noted earlier, the potential for 
reducing physiological, psychological, and social distress with proper treatment is 
clear. 
This finding is worth a more detailed look because the efforts of 
psychology were focused on "cure" of a functional conversion disorder until 
recently. Many in the field believed that SD was a functional disorder only. Murry 
et al. (1994) clarified Cannito's (1991) original study, which noted elevated 
somatic and emotional complaints from SD patients versus controls. Murry et al. 
found that depression and anxiety levels were significantly reduced for SD 
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patients both one week and two months post Botox treatment. Because 
depression and anxiety are also constructs of an underlying cluster of factors, 
this study would be an excellent clarification of statistical technique and scale 
use. 
Thirty-two patients with SD at a voice clinic were chosen because they 
had received no previous Botox treatment, their symptoms had existed for over 
one year, they were not under psychiatric care, and they did not have any other 
voice disorder. Scales used included the Somatic Complaints Checklist, the 
State-Trait Anxiety Inventory (standardized on 1,838 working adults), and the 
Self-Rating of Depression Scale (SDS). The SDS was chosen by the authors 
because of a study which showed it to be a better predictor of a diagnosis of 
depression (as defined by the DSM-III in 1985) than the more well known BDI 
and MMPI (Murry et al., 1994). In addition, note that the State-Trait scale 
provides scores for both state anxiety and trait anxiety. 
Each of the three scales was given to subjects pre-injection, at one week, 
and at two months post-injection. Of interest to this writer's study, 30 patients had 
ADSD (U), one had ABSD (U), and one had MixedSD. This study separated 
ADSD (U) from the other types as a confounding variable of several underlying 
factors related to QOL. Another confounding variable is that there is variability in 
the effect of Botox. 
The authors pursued three paths statistically: To compare subjects to 
controls on measures of (a) Somatic complaints, (b) Anxiety, and (c) Depression. 
Fisher's T-Test (one tailed) was used. When there are fewer observations than 
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practically needed for a Chi Square Test (n = 5 for any contingency), the T-Test 
can provide a better measure of significance. In addition, Pearson's Product 
Moment Correlation Coefficients were used to see whether the present sample 
had an abnormal pattern of inter-correlations related to the affective variables 
mentioned. The researchers found statistically significant differences existed 
between SD subjects and controls on depression, state, and trait anxiety 
measures. The authors noted that somatic complaints were elevated, but not to 
statistical significance. In addition, the Pearson's correlation test showed a 
common emotional factor score of SD patients not found in controls to a 
significant difference. 
Analysis of Variance (ANOVA) was used to measure whether there were 
significant changes in the affective variables post-Botox treatment. SD patients 
were grouped based upon pre-Botox severity level (the authors assumed that 
only those elevated pre-Botox would possibly change). This measured;the 
between subjects effect. A two-way repeated-measures analysis of variance 
method was used. The repeated measures (the within-subjects effect) were 
depression and anxiety scales before and one week after. The result was that the 
cutoff score for the SDS scale (which is 40) provided the dividing line for severity 
of depression for the authors for the two-way analysis of variance. Significantly, 
the authors pooled the data across gender because there were not significant 
score differences by gender. Depressed patients improved significantly (p < 0.05) 
on each affective measure (depression, state, and trait anxiety) one week post-
Botox. Depressed patients differed significantly on all affective measures pre-
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Botox, but did not differ significantly post-Botox from previously non-depressed 
subjects. For somatic complaints, there was not a significant difference in 
depressed (40 or over) and non-depressed groups. 
ANOVA was again used to test the stability of all affective measures from 
one week to two months after the treatment. In this case a one-way repeated 
measures ANOVA was used because severity of affective measures did not 
need to be controlled. There were no significant differences in the comparisons. 
Somatic complaints, trait anxiety, and depression were stable in score. State 
anxiety scores rose but not to the level of statistical significance. 
Because of the multiple scaling (somatic, depression, and anxiety scales 
X2) the ANOVA provided a comparison of multiple factors with each other, and 
provided the statistical ability to separate out two different groups' pre-Botox, to 
eliminate diluting of the effect from those who were not depressed. Fisher's T-
Test provided a better analysis than Chi Square for a data set with small values, 
which would make Chi Square calculations questionable. The Pearson's 
Correlation again provided the statistical ability to detect affective factor 
commonality present in those with SD missing from controls (1994). 
Possible Adjunct Treatments to Botox Injection 
However, it is also apparent that current Botox treatment is only 
"moderately" effective, and is dependent on the patient and treatment condition 
(Boutsen et al., 2002). As discussed earlier, even for the ideal patient and 
outcome, there may be gaps in optimal voice both immediately after injection and 
prior to the next needed injection. As mentioned earlier, ABSD (U) patients also 
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must contend with an average of one month less benefit than ADSD (U) patients, 
and more importantly, less positive symptom management even when the Botox 
is in the effective stage (Blitzer et al., 1998). Although methods to treat the ABSD 
(U) form of SD have been developed (Rontal et al., 1991), they are not as 
effective as treatment for ADSD (U). 
It is possible that a form of treatment attempted unsuccessfully to relieve 
the primary symptoms of SD will provide an adjunctive treatment to current Botox 
therapy. Speech therapy is not considered effective by the majority of the 
medical community for the primary symptoms of SD, but it is considered very 
effective as an adjunctive treatment (Murry & Woodson, 1995). Indeed, if the 
Botox has minimized symptoms, perhaps speech therapy addresses the "bad 
habits" that persons use to compensate for the SD. Speech therapy does attempt 
to address the hard glottal attacks and changes in pitch and breathing pace, for 
example, that compensate for the vocal spasms (Murry & Woodson; Silverman et 
al., 2006). 
MTD treatments might apply and be instructive here, because this 
dysphonia may be a result of poor voice hygiene as well as muscular tension. 
Roy et al. (1996) and Dromey et al. (2008) outlined the effectiveness of laryngeal 
massage and manipulation for MTD but not direct symptoms of SD. However, 
would it be effective as an adjunct to Botox treatment? Altman, Atkinson, and 
Lazarus (2005) contend that poor breath support, inappropriate low pitch, and 
significant cervical neck tension characterize MTD. These are similar to some of 
the overcompensation behaviors of a person with SD. 
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In a presentation at the Regional Symposium on Spasmodic Dysphonia in 
Tampa (2/16/2008), Freeman-Levay, M.A., CCC-SLP, outlined a strategy for 
post-Botox treatment that utilizes behavioral voice therapy to reduce the 
symptoms, compensatory behaviors, and musculoskeletal tension that comprise 
the process of compensating for the laryngeal spasms. Encouraging patient 
involvement in counseling and support groups was also a part of the treatment 
plan. The treatment is carried out for five distinct sessions, beginning three 
weeks after the Botox injection to avoid the initial side effect of breathiness and 
hoarseness. Both the use of speech therapy post-Botox, as well as the 
importance of support groups and counseling, merit further study as promising 
avenues to improving treatment. 
Can biofeedback, which is very effective for many forms of dystonia 
(Maryn, De Bodt & Van Cauwenberge, 2006), but not for primary symptoms of 
SD (Henschen and Burton, 1978), be effective for SD in an adjunctive role? Can 
progressive relaxation, a relatively simple cost-effective technique to teach and to 
learn, be effective for SD in an adjunctive role? Research has suggested more 
than one effective method of relaxation and mind-body intervention (in addition to 
laryngeal massage, biofeedback, and progressive or deep muscle relaxation), 
such as hypnosis, therapeutic massage, and meditation. 
Another program that might offer promise is the Sircle technique for 
neurophysiological retraining. A very thorough assessment is made for 
individuals who have developed muscle pain as the result of repetitive activity 
(although this is a separate condition from Carpal Tunnel Syndrome). Muscle 
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tension is evaluated using EMG Biofeedback, and then the patient is coached 
thoroughly on the techniques of autogenic imagery. The patient's critical role in 
the treatment is emphasized, and office visits are generally scheduled once 
weekly. After about 9 weeks, the sessions are cut to once or twice monthly. 
Anecdotal reports from a rheumatologist working with these patients are that 
there was a 90% success rate (G. Chartrand, personal communication, 
4/8/2008). 
This kind of assessment and biofeedback might prove beneficial to those 
with SD post-Botox or those with MTD. The autogenic relaxation training, when 
part of a comprehensive program as outlined above, may provide extension of 
Botox benefit. Relaxation training is a part of some post-Botox speech therapy 
(Freeman-Levay, 2008). However, what if the training were more comprehensive 
and geared to integrate into the patient's daily lifestyle? 
Adjunct Psychological Interventions to Botox Injection 
Psychological interventions may assist the person with SD in shifting from 
a struggle with the primary symptoms of SD to learning how to cope with the 
variability of Botox treatment. For example, de Jong et al. (2003) present a 
helpful psychological cascade model for the treatment of voice disorders. The 
authors adapted a three-stage model of adjustment to voice disorders from the 
work of Anderson (1995) with chronic back pain. This model focuses on the 
psychological stress around losses from before the onset of symptoms. De Jong 
et al.'s three-phase model views the voice disorder as causing a grief reaction 
with three stages: threat, falling into a pit, and finding renewal (see Table 1). 
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Table 1 
The Psychological Cascade Model 
Stages of Coping with the Voice Disorder Grief Characteristics 
Stage 1: Voice Disorder as a Threat Fear of loss, search for help, isolation, 
depression, exhaustion 
Stage 2: Falling Into the "Pit" Surrender to the loss-Giving in without 
giving up. 
Stage 3: Renewal Maximum recovery in physical, 
functional, social, and psychological 
domains. 
After introducing the psychological cascade model, de Jong et al. (2003) 
described their study of 76 teachers with a voice disorder. The researchers found 
that if physical and functional intervention have been attempted and the voice 
disorder is determined to be chronic, it is then important to review where that 
person is in the cascade model. Identification of current threats (Stage 1), other 
factors inhibiting adjustment, and mal-adaptive coping strategies should be 
addressed (de Jong et al.). If, as hypothesized, ABSD (TR) treatment is even 
less effective than ADSD (TR) treatment, this model may help a patient 
understand the need to accept the physical, psychological, emotional, social, and 
functional losses. 
Based upon the model proposed by Baylor et al. (2005), we can juxtapose 
their domains of physiological, personal, and social QOL (and their systemic 
ABSD v. ADSD/Quality of Life Issues 4 9 
interaction together) with the psychological cascade model and its assessment of 
patient coping with physical (physiological), psychological and emotional 
(personal), and social and functional (social) losses (see Figure 1). In their 
qualitative study, Baylor et al. identified common struggles that a clinician can be 
aware of in order to help that person move through the cascade. 
Personal Soc ia l 
Figure 1: The biopsychosocial model of SD effects. 
As one example, persons with SD must get used to a very different voice. 
They must deal with personal feelings like embarrassment and frustration, 
physiological struggles with fatigue during extended talking, and functional and 
social consequences on the job and in their social life (Baylor et al., 2005). 
Remember that those with a voice disorder are often subject to attitudinal bias 
(Amarpreet & Rochet, 2000; Blood et al., 1979). 
Another example is a common struggle for SD patients is the knowledge 
that they are not being correctly represented by their voice (Baylor et al., 2005). 
Someone who is firm in their opinion and not intimidated may have a quavering 
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voice with TR, easily interpreted by others as fear. Many are forced to adapt 
functionally with a job change and socially by having less contact, reducing social 
and community roles in which speaking is key, or avoiding the telephone. 
Addressing issues like these requires getting the best possible medical 
help, and then adapting psychological attitudes around the changes, adjusting 
social and functional roles in order to maximize benefit, and maintaining helpful 
treatments and good habits to be most comfortable physiologically. Because 
assessment and lifestyle counseling is not yet acknowledged in the literature for 
SD, this is an area that needs further exploration, especially for those who 
experience less effective treatment and management of troubling symptoms. 
While several psychological counseling theories and perspectives can come into 
play here, the use of the psychological cascade model provides one perspective 
on the usefulness of this kind of intervention. The work of de Jong et al. (2003) 
validated the perspective that those with persistent vocal problems often struggle 
in the three recognized domains of physiological symptoms, psychological 
issues, and social functioning of all kinds. 
In a study of chronically ill patients, the use of social support was found to 
improve health measures of physical functioning and emotional well-being over 
time, regardless of age. Researchers have emphasized identifying and dealing 
with psychosocial problems as a key factor in maintaining the health of persons 
with a chronic illness (Sherbourne, Meredith, Rogers &Ware, 1992). Maija and 
Uchino (2008) reviewed research on social support and found a relationship 
between social and emotional support and health. More research is needed on 
ABSD v. ADSD/Quality of Life Issues 51 
the use of support, both professional and peer-to-peer, in assisting those with SD 
to improve their QOL. Currently, the standard recommendation involves 
botulinum toxin injection and speech therapy, but does not emphasize crucial 
areas of psychosocial coping (Murry & Woodson, 1995; Silverman et al., 2006). 
Chapter Summary 
As discussed previously, no clear pre-morbid demographic variables 
appear to exist aside from SD patients being mostly female, older, having a 
higher incidence of childhood virus than the norm, and a higher incidence of 
essential tremor and writer's cramp. However, no specific hereditary or 
environmental variables emerged at a significant level to explain the etiology of 
SD (Schweinfurth et al., 2002). 
Researchers appear to be closing in on the etiology of SD, focusing 
currently on the pathway between the cerebral cortex and medulla oblongata, as 
well as the flow of reflex activity (Simonyan et al., 2008). Still, there is no 
conclusive understanding of etiology. The treatment of choice currently is 
injection into the vocal chords with botulinum toxin accompanied by speech 
therapy to enhance the result of the injection (Murry and Woodson, 1995; 
Silverman et al., 2006). The lack of understanding of etiology directly influences 
the current form of favored treatment, which seeks to minimize symptoms rather 
than provide a cure. 
SD significantly affects physiological, psychological/emotional, and social 
areas of life. Voice related QOL scales have been used to understand the 
influence of SD on QOL in a quantitative way. Hogikyan et al. (2001) have 
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demonstrated the effectiveness of one of these scales (the V-RQOL) in 
understanding the current QOL of the subjects under study. 
Research to date has not yet separated the different types of SD 
sufficiently with regard to the effectiveness of treatment on QOL in the different 
diagnoses of ABSD (TR) and ADSD (TR), controlling for important variables. An 
opportunity exists to increase understanding of the differences between ABSD 
(TR) and ADSD (TR), which will raise questions about effective symptom 
management differences, and increase understanding about how the two 
differing diagnoses affect QOL. The next chapter presents the methodology of 
this quantitative study surveying persons with both kinds of SD while controlling 
for key variables that could have confounded the analysis of the data. 
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CHAPTER 3 
Methodology 
Overview 
This chapter will cover the methodology of the study, beginning with a 
description of the research questions/hypotheses, sample population, collection 
method, and rationale behind using these methods. Next, important aspects of 
internal validity that were taken into account, such as types of variables 
considered and their operational definitions follow. The management of key 
ethical questions will then be reviewed regarding the collection, storage, and use 
of respondent information. 
Restatement of the Problem 
The study described below attempted to assess the specific influence SD 
has on QOL for those with ABSD (TR) as compared to those with ADSD (TR) 
after treatment with Botox. The literature is clear that there is a difference in the 
effectiveness of current treatment for ADSD (U) and ABSD (U) based upon 
clinical observation (Blitzer et al., 1998; Boutsen et al., 2002). It is quite possible, 
from reviewing the literature, that additional interventions may enhance QOL for 
those who are not as effectively treated with the current treatment of choice, 
based upon personal perception of QOL. 
Statement of the Research Questions/Hypothesis 
Previous research has measured QOL but has not separated out the 
types of SD alone and in combination in QOL studies. Researchers have noted 
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specifically that Botox works best for ADSD (U), based upon clinical measures 
(Blitzer et al., 1998; Boutsen et al., 2002). 
Researchers have consistently studied ADSD (U) by itself because of the 
much larger sample sizes and the assumption that ABSD (U) and ADSD (U) are 
not alike in their effects on the individual. The research question of this study 
asked: 
Research Question 1: To what extent is there a difference in QOL as 
measured by the V-RQOL for ABSD (TR) and ADSD (TR) for those with Botox? 
Based upon the results obtained from the study with regard to Research 
Question 1, further post-hoc analysis was done to more clearly explain the result 
of the initial hypothesis testing. Below, six additional research questions were 
framed and studied in order after the result of the initial study on research 
question 1 was obtained. The additional six research questions asked were: 
Research Question 2: To what extent is there a difference in QOL as 
measured by the V-RQOL subscale scores of Physical Functioning or Social 
Emotional Functioning for ABSD (TR) and ADSD (TR) for those with Botox? 
Research Question 3: To what extent do the demographic characteristics 
(duration, age, side effect, severity, and gender) of the participants significantly 
predict the QOL as measured by the V-RQOL? 
Research Question 4: To what extent is there a difference in QOL as 
measured by the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR versus 
ABSD and ADSD? 
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Research Question 5: To what extent is there a difference in QOL as 
measured by the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR versus 
ABSD and ADSD without Botox? 
Research Question 6: To what extent is there a difference in QOL as 
measured by the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR, compared 
to ABSD and ADSD with Botox? 
Research Question 7: To what extent is there a difference in QOL as 
measured by the V-RQOL between ABSD and ADSD with Botox? 
Based on these research questions, the hypothesis for this study is: 
H1: There is a statistically significant difference in QOL as measured by 
the V-RQOL for ABSD (TR) and ADSD (TR) for those with Botox. 
HO: There is no statistically significant difference in QOL as measured by 
the V-RQOL for ABSD (TR) and ADSD (TR) for those with Botox. 
In line with the research questions above, the post-hoc hypotheses tested 
below were studied in order: 
H2: There is a statistically significant difference in QOL as measured by 
the V-RQOL subscale scores of Physical Functioning or Social Emotional 
Functioning for ABSD (TR) and ADSD (TR) for those with Botox. 
HO: There is no statistically significant difference in QOL as measured by 
the V-RQOL subscale scores of Physical Functioning or Social Emotional 
Functioning for ABSD (TR) and ADSD (TR) for those with Botox. 
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H3: The demographic characteristics (duration, age, side effect, severity, 
and gender) of the participants predict the QOL as measured by the V-RQOL to 
a statistical significance. 
HO: The demographic characteristics (duration, age, side effect, severity, 
and gender) of the participants do not predict the QOL as measured by the V-
RQOL to a statistical significance. 
H4: There is a statistically significant difference in QOL as measured by 
the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR versus ABSD and 
ADSD. 
HO: There is not a statistically significant difference in QOL as measured 
by the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR versus ABSD and 
ADSD. 
H5: There is a statistically significant difference in QOL as measured by 
the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR versus ABSD and 
ADSD without Botox. 
HO: There is not a statistically significant difference in QOL as measured 
by the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR versus ABSD and 
ADSD without Botox. 
H6: There is a statistically significant difference in QOL as measured by 
the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR, compared to ABSD and 
ADSD with Botox. 
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HO: There is not a statistically significant difference in QOL as measured 
by the V-RQOL for MixedSD (TR), ABSDTR, and ADSDTR, compared to ABSD 
and ADSD with Botox. 
H7: There is a statistically significant difference in QOL as measured by 
the V-RQOL for ABSD and ADSD with Botox. 
HO: There is not a statistically significant difference in QOL as measured 
by the V-RQOL for ABSD and ADSD with Botox. 
The ancillary investigation was conducted after the initial hypothesis was 
tested in order to attempt to provide some explanation for the result. Data for 
variables which have been correlated in previous research with QOL, or were 
thought by this researcher to play a possible role in influencing QOL were also 
gathered. After testing the initial hypothesis, further analysis of the these key 
variables of age, gender, duration, severity, and side effects was done. In 
addition, the ancillary variable of MixedSD (TR) was later added to the analysis 
as well. 
Description of the Research Design 
The research design that was used in this study was that of a quantitative 
comparative design (Creswell, 1994). The reason for using the comparative 
research design is that it provides the researcher with the ability to determine 
whether there are differences in the average scores for two or more independent 
populations (Cozby, 2001). In the context of this study, the independent 
populations consisted of participants who were observed to have either ABSD 
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(TR) or ADSD (TR). The average scores, which were then compared with one 
another, were the QOL as measured by the V-RQOL survey instrument. 
When the independent variables are categorical (i.e., have two or more 
specific categories: nominal or ordinal) the researcher can determine if 
differences existed between the two or more groups (Moore & McCabe, 2006). 
For this reason, the comparative design is appropriate because one would be 
able to determine if there are any differences between the two groups with 
respect to their QOL scores as measured by the V-RQOL. 
In addition, a quantitative research design was chosen because a 
comparison was made between an independent variable and a dependent 
variable. This means that the researcher was able to assign numerical values to 
the predictor and outcome variables to make a comparison between the two 
types of variables (Creswell, 1994). The values for the independent and 
dependent variables were obtained by using a survey instrument that was 
designed to measure the QOL as well as the independent variables in the study. 
Therefore, the resulting variables could be assessed by using various statistical 
methods. 
The study was designed in such a way that best efforts were taken to 
screen for all known intervening variables from the literature. While the variables 
were not initially to be analyzed in this study, except for Botox treatment, they 
were gathered in the case that the data required further analysis. Hogikyan et al., 
(2000) had previously found that voice disorder patients, uncontrolled for age, 
severity of the SD, and side effect of SD, could be assumed to be of equal 
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variance. Therefore, it was not necessary to include the variables in the initial 
hypothesis testing. 
Operational Definition of Variables 
The independent variable for the initial hypothesis test consisted of the 
two most frequent occurrences among the diagnoses of SD, ADSD (TR), and 
ABSD (TR). In addition to the two types of SD mentioned in the paragraph 
above, participants could be diagnosed with MixedSD, or MixedSD (TR). Those 
respondents who identified a primary tremor only were excluded from the study. 
Those with MixedSD (TR) were excluded from the initial hypothesis testing. In 
subsequent statistical analysis used to explain the result of testing the initial 
hypothesis, MixedSD (TR) was included in order to examine the data for possible 
intervening variables that could explain the first result. 
On the survey instrument, respondent selection into the categories of 
ADSD (TR) and ABSD (TR) was based upon their self-report. The other type that 
was included on the survey was a MixedSD (TR). There was also a choice of 
"tremor only." This accounted for the six types found in the literature. The "tremor 
only" category is considered to be a different condition and was not studied. An "I 
don't know" category was also included on the survey to eliminate respondents 
who might guess at a type if forced to do so (See Appendix A, survey question 
3). 
The dependent variable was the mean of V-RQOL scores for either ABSD 
(TR) or ADSD (TR). This is how QOL was operationally defined. The mean was 
calculated from the algorithm provided with the scale (Hogikyan & Sethuraman, 
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1999). The independent variable was whether the person had ADSD (TR) or 
ABSD (TR). This was operationally defined by how the person designated 
themselves on the proposed survey. The survey included a radio button for all 
seven types mentioned above. The respondent could also select a "don't know" 
radio button. Those who chose "don't know" and also could not specify the type 
in the "don't know" section by description were eliminated. The respondents 
could select as many of the types as they chose. 
Data regarding whether the respondent was receiving Botox treatment 
was collected in order to control for this significant intervening variable in the 
initial hypothesis. Also, data about six other possible intervening variables was 
collected. This data was collected in order to be able to further explain the result 
of the initial hypothesis if needed. These variables are defined below. 
1. Botox treatment: (Botox) The most compelling variable discussed so 
far that affects QOL is whether or not a person has been treated with 
Botox injection into the vocal chords (Benninger et al., 2001; 
Bhattacharyya & Tarsi, 2001; Blitzer et al., 1998; Boutsen et al., 2002; 
Courey et al., 2000; Futrovsky, 1992; Hogikyan et al., 2001; Langeveld 
etal., 2001; Liuetal., 1998; Ludlow et al., 1988; Murry et al., 1994; 
Rubin et al., 2004; Truong et al., 1991; Watts et al., 2005). This 
variable was operationally defined as the respondent's identification of 
whether or not they are currently receiving Botox treatment. 
2. Surgery: (surgery) A recent trend to emerge in the literature is surgery 
that is effective for treating SD in the long term (Allegretto et al., 2003; 
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Berke et al.,1999; Chhetri et al., 2006). Although this surgery 
(Laryngeal Nerve Reinnervation-Denervation), has the best 
documented long term outcomes, Myectomy (Koufmann et al., 2006) 
and Electrocautery also show promise (Ramacle et al., 2004). It was 
determined, however, from reviewing the literature, that if a person was 
receiving Botox after surgery, the surgery was not successful. 
Therefore, those receiving Botox who had been through surgery were 
counted in the data. This was operationally defined as the 
respondent's identification of whether or not they have ever received 
surgical treatment specifically for SD. 
3. Side Effects of Botox, or Varying Efficacy between Patients and 
Treatment Conditions: (side effect) Wingate et al. (2005) studied 13 
subjects with ADSD and found no significant difference after Botox 
injection in QOL scale score. However, the authors also argued that 
side effects of the Botox injections may have skewed the data with this 
small sample. Three of the 13 subjects had significant side effects. 
Side effects and a varying level of efficacy of Botox treatment between 
patients and between treatment conditions appear to have influenced 
other clinical studies of Botox effectiveness as well (Bielamowicz et al., 
2002; Blitzer et al., 1998; Boutsen et al., 2002; Coureyet et al., 2000; 
Lundy et al., 1997). The operational definition of this variable was the 
respondent indicating that they have had side effects from Botox 
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treatment that significantly lessened the positive effects of the 
treatment. 
4. Age: (age) The Wingate et al. (2005) study also pointed out a possible 
relationship between age and SD QOL. This relationship may be 
confounded by small sample size and by skewed data having to do 
with side effect and varying effectiveness, but it cannot yet be ruled out 
as a variable which would significantly affect result. Tisch et al. (2003) 
also found, in a retrospective sample of 169 clinic patients, that age 
potentially would be a confounding variable. This was operationally 
defined as the respondent's report of their chronological age in full 
years. 
5. Gender: (gender) While the preponderance of SD patients are female 
(Adleretal., 1997; Blitzer & Brin, 1991; Schweinfurth etal., 2002), 
; gender does not yet appear to be a confounding variable, either from 
lack of variation of benefit by gender after Botox treatment (Boutsen et 
al., 2002), or by neurological testing of severity (Schaeffer, 1983). The 
operational definition of this variable was the respondent's 
identification of their gender as male or female. 
6. Severity of SD: (severity) Severity of SD symptoms also can be a 
significant intervening variable (Gundel et al., 2007; Jones et al., 
2006). If so, this would change not only QOL but also possibly the 
treatment plan (Murry & Rosen, 2000). This variable was operationally 
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defined as the respondent's identification of their perception of their SD 
diagnosis level as mild, moderate, or severe. 
7. Duration of SD: (duration) Duration does not appear to have been 
examined in the literature reviewed for this study. However, as 
indicated in the discussion of the Cascade Model, persons who have 
had SD longer might naturally be better adjusted psychosocial^ to 
their condition. This might lead to significant affects on QOL. This 
variable was operationally defined as the respondent's identification of 
the number of full years that they have had symptoms of the condition 
ofSD. 
In the statistical analysis of the hypothesis, treatment with Botox will be a 
crucial variable that will be controlled. After this analysis, the variables of 
duration, severity, age, side effect, and gender will be further analyzed. Surgery 
will not be considered to be a significant variable if the respondent is currently 
receiving Botox treatment, because a return to Botox treatment after surgery has 
been used to define an unsuccessful surgery (Chhetri, Mendelsohn, Blumin & 
Berke, (2006). The variable of MixedSD (TR) was also added post-hoc in order to 
compare differences in QOL between all types gathered in the survey. 
Description of Materials and Instruments 
Type of SD was measured by self-report on the survey instrument (see 
Survey Question 3 in Appendix A). The survey also measured whether the 
respondent currently received Botox treatment by respondent self-report (see 
Survey Question 6 in Appendix A). QOL was measured by the V-RQOL 
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developed by Hogikyan et al. (1999). The V-RQOL requires an algorithm 
calculation (see Appendix C). A V-RQOL lower score represents a lower QOL. 
Mean V-RQOL scores averaged in the 90s for normal controls, 70s for treated 
patients, and 30s for untreated patients. This includes the V-RQOL Total score, 
Physical Functioning score, and Social-Emotional score (1999). The V-RQOL 
has 10 items that were defined as measuring a Total Score, and a score for the 
subscale Physical Effects, and the Social-Emotional Functioning subscale. The 
10 items on the V-RQOL are based on a 5-point scale that range from 1 
representing "None, not at all" to 5 representing "Problem is as bad as it can be". 
Some of the example questions that are provided on the V-RQOL include, "I 
have trouble speaking loudly or being heard in specific situations" and "I avoid 
going out socially (because of my voice)" (see Appendix C). 
Psychometric Properties of the V-RQOL 
Discriminant validity for the V-RQOL was tested by comparing voice 
disorder groups to controls, with scores significantly lower for those with voice 
disorders. Convergent validity was measured by comparing V-ROQL Social-
Emotional Functioning, and Physical Functioning scores and VHI total scores 
with a self-rating of voice quality (Hogikyan et al., 2005). Franic et al.(2005) found 
both the V-RQOL discriminant validity and convergent validity to be satisfactory 
in their analysis. It will prove important to note at this point that this convergent 
validity does not necessarily extend to professional observer ratings of voice 
quality (Lee etal., 2003). 
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The V-ROQL clinical data has been demonstrated as responsive with two 
different voice disorders (Hogikyan et al., 2001; Hogikyan et al., 2000). V-RQOL 
will pick up positive and negative changes in the QOL construct over time. This is 
significant because QOL scores can improve significantly after treatment with 
Botox (Courey et al., 2000; Hogikyan et al., 2001; Rubin et al., 2004). Hogikyan 
and Sethuraman (1999), as mentioned by Franic et al., reported a Cronbach's 
alpha of 0.89, and the Pearson's Product correlation was 0.93. 
Hogikyan and Sethuraman (1999) contended that a relationship exists 
between the V-ROQL and QOL (construct validity) through a correlation between 
subject self-perceived voice quality rating and V-ROQL domain scores and total 
score at a significance level of p < 0.001. 
Selection of Subjects 
The sampling frame was the database of the NSDA. For this reason, a 
non-probabilistic convenience sampling method was used. This is because the 
information that was used for this study was taken from a pre-existing database 
that was established by the NSDA. The advantage of using the convenience 
sampling method compared to a probabilistic or random sample was that the 
researcher was able to obtain participants or observations for the study while 
spending little effort and time on selecting random participants (Cozby, 2001). 
The sample was weighted more heavily toward ADSD (TR) as opposed to 
ABSD (TR) and Mixed (TR). The NSDA provided an e-mail list of persons 
belonging to the organization. Feeley (2008) conducted a survey of this 
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population for use in a book. Feeley used a methodology similar to the proposed 
distribution methodology for this study through the NSDA. 
This study used the membership database of the NSDA. A survey link and 
invitation to participate e-mail was sent to the membership by the NSDA. The 
respondent clicked on the link, which went directly to the survey on the Survey 
Monkey website. The first page of the survey contained the informed consent 
document (Appendix A). If the respondent agreed to participate, a box was 
checked and the respondent was then sent to the survey page. The survey's first 
page also offered options to exit the survey without taking it, and to obtain 
contact information from the researcher. 
The respondent completed the survey, and the data was gathered in the 
website in the researcher's personal account. When the study was closed, the 
data was analyzed.. A total 395 participants agreed to the terms of the study by 
selecting "I have read the above information and I choose to participate in this 
study". The data was then downloaded in an Excel spreadsheet. The originality 
of the spreadsheet download was also verified by Dr. Darlene Andert, PhD, of 
Florida Gulf Coast University, Fort Myers, Florida, who supervised the download 
and kept a personal copy of the original spreadsheet. The relevant sections were 
transferred to SPSS software for analysis. Although 395 participants agreed to 
the study, sample amounts comprising valid information for each of the questions 
on the survey instrument was lower. Each research question eliminated 
respondents who did not answer the key variable survey questions associated 
with that hypothesis. The specific method of analysis will be described below. 
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In a power analysis conducted prior to the study for the initial and only 
proposed hypothesis (effect size = 0.85, p < 0.05, allocation ratio = 0.35 ) the 
smallest effective sample size could be 80 according to the G Power 3.0.10 
software, with 59 in the ADSD group and 21 in the ABSD group, projecting for a 
one tailed t-test of independent means. The reason that most studies have not 
attempted to study ABSD (TR) is the difficulty with obtaining a sample size large 
enough in any one clinic, where sample sizes are smaller unless a retrospective 
review is done. Although the sampling model for this study relied on available 
subjects and is a non-probability sampling model, the sample size was ample for 
the power requirements noted. In addition, a previous researcher found that with 
dysphonic patients, there is not a statistically significant sample variance, even 
between treated and untreated patients (Hogikyan et al., 2000). 
Data Collection Procedures 
i The survey instrument used for this study containing the V-RQOL was 
developed in the proprietary Survey Monkey website. An e-mail was distributed 
to the mailing list provided by the NSDA containing the link to the survey, asking 
for respondent participation (see Appendix B). The first page of the survey 
contained the informed consent form, and the second page contained the survey 
instrument (see Appendix A). The second page was only accessible by those 
who consented to participate in the study. 
- The Survey Monkey website captured each response, and collected 
variable and intervening variable information, as well as V-RQOL raw data. The 
data was collected on an Excel Spreadsheet, which was downloaded from the 
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Survey Monkey website. The data was sorted, and then copied into a worksheet 
from the Statistical Package for the Social Sciences (SPSS) software for 
calculation. 
The survey was reviewed and tested continuously throughout 
development, especially to screen for appropriateness of closed or open-ended 
questions on any one item, clarity of item, avoidance of double barreled 
questions, review of whether respondents were competent to answer, making all 
questions relevant, making questions as short as possible, avoiding negative 
wording, and avoiding bias (Babbie, 1998). Pre-testing of the survey was carried 
out continually on a small sample of professors at Hodges University in Fort 
Myers, Florida who are familiar with survey research and design in order to refine 
the instrument. The data obtained for this study will be retained for a period of 3 
years where it will then be destroyed by deleting the files from the computer. 
Discussion of Data Processing 
The data analysis for the study was performed in the statistical software 
package SPSS Version 16.0®. Descriptive statistics are used in this study in 
order to examine the distribution of the variables included in the study. The 
descriptive statistics that are used include measures of central tendency, which 
in this case is the mean and standard deviation of the V-RQOL scores. Other 
descriptive statistics that were used in the analysis are frequency tables that 
provide information on the number and percentage of participants by type of SD 
diagnosis. 
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Independent samples t-test. The independent samples t-test was initially 
used to determine whether there was a statistically significant difference between 
ABSD (TR) and ADSD (TR) with respect to mean V-RQOL score. By using the 
independent samples t-test for this purpose, the statistical significance of the 
difference between the two means was evaluated. 
To test the initial hypothesis, the data was segregated into ABSD (TR) and 
ADSD (TR) groups, and was controlled for use of Botox. Then, as an ancillary 
analysis, the data was evaluated to determine whether these groups were 
significantly different on the Physical Functioning subscale or the Social-
Emotional Functioning subscale. 
Next, the data was segregated into analyzing the MixedSD (TR). Also 
included in this group, even though not a mixed diagnosis, were ABSDTR and 
ADSDTR. One way t-tests of independent means were performed on MixedSd, 
ABSDTR and ADSDTR respondents versus those with ABSD and ADSD. This 
first t-test used the entire sample regardless of whether or not they were 
receiving Botox treatment. The second t-test analyzed the two groups only if they 
had not received Botox. The third t-test analyzed the two groups only if they had 
received Botox. Based on these results, and as a check on the initial hypothesis 
test performed on ABSD (TR) and ADSD (TR), simple ABSD was compared to 
simple ADSD, removing the TR combinations used in the initial test of the 
hypothesis (see Tables 8, 9, 10, and 11 and Appendix F). 
Multiple regression analysis. Multiple regression was used in post hoc 
testing to determine if several categorical independent variables (age, gender, 
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severity, side effect, and duration) were significant predictors of the dependent 
variable V-RQOL score while taking into account the other unknown independent 
variables in the model. 
To make sure that the most parsimonious model was obtained for this 
analysis, a stepwise procedure was used. The stepwise regression procedure 
consisted of including variables in the model one at a time and then assessing 
their significance. This process was repeated until all five of the significant 
variables were included in the model. After all the significant variables were 
included, if it was found that a variable was no longer significant after controlling 
for all the other variables that were entered then this variable was removed from 
the model. As a result only the most significant variables were kept in the model. 
Methodological Assumptions, Limitations, and Delimitations 
Limitations of this study will now be described in more detail. Sampling 
scheme and survey methodology, choice of QOL scale and use, generalization of 
data to other voice disorders and other chronic conditions, and the current 
understanding of the etiology and effective treatment of SD will be discussed. In 
addition, the nature of the population under study may be an issue. 
The sampling scheme used the NSDA database. Therefore, subjects self-
selected due to motivation to be active in the NSDA. As one example of a 
confounding variable not considered, what if more motivated, resilient persons 
join health-based organizations and support groups for their chronic condition? In 
this hypothetical example, those who struggle most with the condition would not 
have joined NSDA, and would not be in the sample, inflating V-RQOL average 
ABSD v. ADSD/Quality of Life Issues 71 
scores. Conversely, the opposite may be true. Those who are especially troubled 
may join for support purposes, while those who are doing well may not have such 
a motivation. In addition, those in the NSDA may have had SD for a longer 
duration than the average person. This may bias the sample because of a 
possible but unknown characteristic of a person with SD who would join the 
NSDA as opposed to one who would not (Babbie, 1998). 
Another concern is that the survey was distributed by e-mail. This 
presupposes a competency with internet skills and an interest in responding to 
online surveys. Those who are not online would not participate. Although it was 
hoped that this distinction would not be a confounding variable, it is possible that 
older persons would be less likely to use the internet for communication. As 
discussed earlier, age was indeed a possible confounding variable for this study, 
again theoretically raising the V-RQOL average scores. Another age related 
concern had to do with the V-RQOL. One of the ten questions asks the 
respondent to rate if "I have trouble doing my job or practicing my profession 
(because of my voice)" (Hogikyan et al., 2001, p. 585). This may bias the data 
set by excluding those who are retired or otherwise are not employed from 
thoroughly completing the V-RQOL. 
The V-RQOL survey itself has been analyzed to have a sufficient degree 
of reliability and validity, however, relationships between the construct of QOL 
and V-RQOL score are approximate. Another issue concerns the survey 
instrument itself. This proposed study will use respondent self-reports to separate 
subjects into the important variable categories. Respondents may be in error as 
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to their diagnosis, for example, the severity of their condition, and other factors. 
Respondent error was possible. In addition, experimenter error in collecting data 
and calculating results was possible. 
Although one study exists that uses the V-RQOL in a sample population 
other than SD (vocal fold paralysis), this is the only published study using the V-
RQOL outside of the SD population (Hogikyan et al., 2001). No evidence exists 
that these results could be generalized to other populations with a non-voice 
related chronic illness. However, the V-RQOL instrument itself was originally 
developed using a sample of 109 patients presenting at a voice clinic with a 
presentation of dysphonia, not specifically SD. In addition, while caution must be 
used in generalizing one chronic health condition to another, the V-RQOL does 
have a moderate (0.51) correlation to the SF-36, a general QOL instrument used 
to assess QOL with a diverse chronic illness population (Hogikyan & 
Sethuraman, 1999). In addition, as discussed earlier, the hypothesis relies on the 
clinical observation of voice function as a predictor of QOL as evaluated by the 
SD patient. This is not a known correlation (Deary et al. 2003). 
Another limitation of the study was that while this study took a granular 
approach to diagnosis, previous studies most often identified only the simple 
types of SD without identifying accompanying TR as well. Therefore, when 
comparing the previous literature to this study, the weakness here is that is it 
assumed, not proven, that associated TR was included in the previous-samples, 
just not identified. 
Ethical Assurances 
ABSD v. ADSD/Quality of Life Issues 7 3 
Each institution is required to have an Institutional Review Board in order 
to make sure that Federal Regulations (National Research Act of 1974) for 
ethical research are followed. Based on many historical problems with obtaining 
subject consent, undue risk to subjects, and other issues, review of the ethical 
standing of a study has become imperative (Ethical Research Conduct, n.d.). 
This section will review the methodology of the study in order to detect possible 
ethical concerns and resulting safeguards. 
Two initial factors about the research are that the research needed human 
subjects and that the research covered sensitive issues such as medical 
diagnosis and perceptions about QOL. Therefore, it was much more practical to 
limit subjects to 18 years of age and older first, because it is very rare for a child 
to have the disorder, and second, because this limitation streamlined the 
informed consent procedure, especially because it would be much more difficult 
to obtain parental as well as child assent and consent online (Ethical Research 
Conduct, n.d.). Adults were also able to make a more competent choice as to 
whether they wish to answer personal questions or choose not to. 
Because there is a mild to moderate risk of emotional upset stemming 
from reflection of the subject on effects of SD on their QOL, it was made clear in 
the informed consent document that assistance was available (see Appendix A). 
The lead researcher (a Licensed Social Worker in the State of Florida) made a 
cell phone number and e-mail address available to subjects who became upset. 
The subjects were also provided with contact information for the Northcentral 
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University Institutional Review Board and the NSDA. No subjects contacted the 
researcher directly for the purpose of counseling support. 
Subjects were possibly motivated to assist in research because it may 
shed light on their condition. It was therefore important to neither overstate nor 
understate the effect of the research on the subject in the informed consent 
document. In addition, it was important to indicate that the subject may elect not 
to participate at any point in all or part of the study, including while reviewing the 
actual survey. The subject was advised that they could elect not to participate 
even after starting the survey (Ethical Research Conduct, n.d.). 
Another crucial issue that was addressed, given the sensitivity of the 
information, was privacy. The NSDA provided their member e-mailing list. 
However, information that contained names, addresses, and e-mail addresses 
was not accessed directly by this researcher. The survey link and an e-mail 
containing informed consent and access instructions were furnished to the 
NSDA. No identifying information such as names or e-mail addresses of the 
respondents was accessed by the researcher, nor was asked for on the survey. 
The survey asked for certain details about subjects' SD diagnosis and the 
effect it has had on their QOL. Data was collected and grouped by identifying 
number, which was not linked to a corresponding name or other identifying 
information. One step taken was to not record e-mail addresses along with 
survey response. The subject was provided only a web link, rather than ability to 
answer the survey directly on the e-mail. In addition, the IP addresses of survey 
respondents were eliminated from data collection as well. The Survey Monkey 
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site also indicates they do not collect data from any surveys on their site (Survey 
Monkey Security, n.d.). Therefore, neither the researcher, nor Survey Monkey, 
which maintains the website for the survey, had access to the identifying 
information about the computer where the survey response originated. 
The most likely point that identifying information about the subject was in 
danger was while accessing the survey, where data might have been intercepted 
by a hacker. This threat required the use of the optional Survey Monkey secure 
socket layer feature. This feature provided encryption in the form of a "tunnel" 
through the internet, making it much more difficult for the information to be 
hacked by an unauthorized person (Survey Monkey Security, n.d.). 
Confidentiality was protected by dissemination of data to public sources only in 
aggregate form. All data was stored on the secure Survey Monkey site, and hard 
copy forms were stored in a locked file cabinet in the primary researcher's home. 
Due to the precautions for privacy previously mentioned, it was not judged 
necessary to apply for a Certificate of Confidentiality (Ethical Research Conduct, 
n.d.). 
Because the survey was voluntary, counseling support was provided, and 
care was taken to give a safe access channel to the survey, there appeared to be 
adequate preparation in the methodology to minimize experimental risk, thus 
increasing the risk to benefit ratio. These steps limited the social and emotional 
risk. There was little apparent physical risk as opposed to other activities of daily 
life, and the minimal economic risk would have been from computer exposure for 
the subject to the internet. However, by using secure socket layer encryption, the 
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same protection used by personal banking sites was used, thus minimizing this 
risk (Ethical Research Conduct, n.d.). 
Informed consent issues for respondents were addressed in the survey 
instrument. The informed consent document had to be accessed before the 
survey could be taken. This informed consent can be found in Appendix A. This 
document covered the crucial aspects of respondent consent to voluntary 
participation and cessation of participation, identification of study purpose and 
caution regarding possible risks. Options were provided for respondents 
regarding questions they had, who to contact other than the experimenter, and 
procedures to follow if the respondent became upset during participation in the 
survey process or afterwards. The text of the introductory e-mail that contained 
the link to the informed consent and the survey can be found in Appendix B. 
In summary, several measures were taken to protect the confidentiality of 
respondent identifying information. The NSDA database of names was controlled 
only by the NSDA. All communication to study participants was channeled 
through the NSDA, unless consent was provided by the participant. 
All responses in the survey instrument were identified by number only. As 
previously indicated, e-mail addresses could not be tracked because a survey 
web-link was provided to the respondent, and configurations in the Survey 
Monkey website make it possible to keep IP addresses anonymous; therefore, 
these Survey Monkey website features eliminate the ability to track to a particular 
computer. Last, because the largest danger to confidentiality is from interception 
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of internet traffic, a secure socket layer encryption tunnel (https) was used to 
connect Survey Monkey to the respondent's computer. 
Any hard copy data was kept in one locked file in the lead researcher's 
home, and only the lead researcher had access to the key. Future dissemination 
of data publicly will only occur in aggregate format. Caution will be taken to only 
disseminate that information if there is a large enough sample to preclude the 
possibility of identifying any one particular response set. 
Chapter Summary 
This chapter outlined the methodology of delivery of the survey to test for 
differences in QOL among those with SD by diagnosis type. A review of the 
relevant literature provided a basis for the rationale used in construction of the 
study. The identification and operation of study variables used previous relevant 
studies insofar as possible. Review of instrumentation included a careful look at 
previous studies and their results with the instrument. 
Sampling strategy and ethical considerations for respondent participation 
and data collection and storage were carefully considered. Survey methodology 
and distribution strategy were discussed. Respondent safety, privacy, 
confidentiality, and informed consent were reviewed for measures taken to 
prevent possible harm to participants, and prevention strategies to minimize the 
chance of harm and to maximize the benefit of the study were discussed. 
Threats to the internal validity were outlined, and the ability of the results 
to be generalized to other conditions and situations was discussed. Included in 
this discussion is a listing of limitations in the study, including issues of 
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practicality and even what is possible and not possible to control for in preventing 
a confounding of the analysis of the data. In the next chapter, a review of the 
data obtained will be presented, discussed, and analyzed. 
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CHAPTER 4 
Results 
Overview 
This chapter presents the analyses of the data as described in chapter 3. 
The initial question of whether there was a significant difference in the QOL (V-
RQOL Total Score) between ABSD (TR) and ADSD (TR) was tested. Next, post 
hoc testing that was done after the testing of the initial hypothesis will be 
described, based upon the variables of age (age), gender (gender), amount of 
time that the respondent has had SD (duration), Botox side effects (Botox Rx) 
and SD diagnostic severity level (severity). Information will be presented that 
analyzes the variables mentioned with regard to V-RQOL scores. 
Next, the chapter reviews a second effort post hoc effort to explain the 
findings from the hypothesis consisted of a review of the larger data set, which 
led to a significant finding outside of the variables already discussed, consisting 
of the difference between pure ABSD and ADSD and all other types of SD. 
These include MixedSD (TR), ABSD (TR), and ADSD (TR). 
Demographic Description of the Sample 
The average age of the entire sample was 52.18 years, with an age range 
from 21 to 88. The sample was primarily female (80.9%). Five percent had the 
mild severity level of SD, 29.5% were moderate in severity, and 24% were in the 
severe category. Thirty-eight percent did not know their severity level. More than 
half (i.e. 59.0 %) of the sample was receiving Botox treatment at the time of the 
survey, 63.2% of the sample at one time had experienced significant side effects 
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of Botox treatment, and 8.5% of the sample had been through a surgical 
procedure specifically for SD. The average respondent had experienced SD 
symptoms for 13.23 years, with a range of less than 1 year to 57 years. It took 
respondents an average of 5.38 years to be diagnosed with SD after symptoms 
started, and the time range was from less than 1 year to 50 years. 
For the diagnosis summary by type presented in Table 2, the entire 
downloaded spreadsheet was sorted into subtotals for all diagnostic categories 
using the Excel subtotals command. The spreadsheet was then reviewed for 
multiple answers on one record. If this occurred, the most complex diagnosis was 
kept and all other multiple answers per record were removed from the subtotals. 
The most frequent type of SD for the sample was ADSD (TR) (41.9%), which 
was followed by ABSD (TR) (25.6%). The remaining 32.5% had some other form 
ofSD. 
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Table 2 
Incidence Percentage of All Types of Diagnosis 
Type of SD 
ABSD 
ADSD 
ABSDTR 
ADSDTR 
ABSD and ADSD 
ABSD and ADSD and 
TR 
Number Reporting 
(Total n = 258) 
66 
108 
17 
24 
30 
13 
Percent of Total 
25.6% 
41.9% 
6.6% 
9.3% 
11.6% 
5.0% 
Results 
The first question asked in this study was whether there was a statistically 
significant difference in QOL as measured by the V-RQOL for ABSD (TR) and 
ADSD (TR) for those with Botox. It was hypothesized that there would be no 
difference between the two groups of participants. To determine if a significant 
difference existed between ABSD (TR) and ADSD (TR), an independent samples 
t-test was conducted analyzing the dependent variable QOL by type of SD. Since 
there were two independent groups in the study, Levene's test for equality of 
variances was conducted. The findings for this test was that the variances from 
each group were not significantly different from one another (p = 0.96). 
Therefore, equality of variances was assumed for the two groups. The results of 
the independent samples t-test showed that there was not a significant difference 
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between participants who had ABSD (TR) compared to participants who had 
ADSD (TR) in terms of their QOL (f(125) = -0.13, p > 0.05). In other words, there 
was no difference in the QOL of participants who were diagnosed with ABSD 
(TR) and participants who were diagnosed with ADSD (TR). A summary of the 
independent samples t-test is presented in Table 3. 
Table 3 
T-test for ABSD (TR) and ADSD (TR) with Botox 
Test Value 
Levene's Test F = 0.003 
Levene's Test Significance p = 0.958 
t-test t = -0.129* 
t-test Significance 0.898 
Standard Error Difference 4.29642 
Note: See Appendix D for SPSS Output. Sample size: ABSD (TR) (n = 41); ADSD (TR) (n = 86). 
Mean V-RQOL by Type: (ABSD (TR) = 43.7195); (ADSD (TR) = 44.2733). *df = 125. 
The second question asked in this study was whether there was a 
statistically significant difference in QOL as measured by the V-RQOL subscale 
scores of Physical Functioning or Social-Emotional Functioning for ABSD (TR) 
and ADSD (TR) for those with Botox. It was hypothesized that there would be no 
difference between the two groups of participants. To determine if a significant 
difference existed between ABSD (TR) and ADSD (TR) for those with Botox, an 
independent samples t-test was conducted analyzing the dependent variable 
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QOL by type of SD. The findings for the Levene's test of equality of variances for 
the Physical Functioning found that the variances from each group were not 
significantly different from one another (p = 0.66). Similarly, the variances from 
each group were not significantly different from one another for the Social-
emotional Functioning scores (p = 0.35). Therefore, equality of variances was 
assumed for the two groups. The results of the independent samples t-test 
showed that there was not a significant difference between participants who had 
ABSD (TR) compared to participants who had ADSD (TR) in terms of their 
Physical Functioning scores (f(125) = -0.45, p > 0.05). In other words, there was 
no difference in the Physical Functioning scores of participants who were 
diagnosed with ABSD (TR) and participants who were diagnosed with ADSD 
(TR). A summary of the independent samples t-test is presented in Table 4. 
Table 4 
T-test of Physical Functioning Scores 
Test Value 
Levene's Test F = 0.195 
Levene's Test Significance p = 0.659 
t-test t = -0.448* 
t-test Significance p = 0.655 
Standard Error Difference 4.29642 
Note: See Appendix D for SPSS Output. Sample size: ABSD (TR) (n = 41); ADSD (TR) [n = 86). 
Mean V-RQOL by Type: (ABSD (TR) = 41.4364); (ADSD (TR) = 43.4109). *df = 125. 
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The results of the independent samples t-test showed that there was not a 
significant difference between participants who had ABSD (TR) compared to 
participants who had ADSD (TR) in terms of their Social-Emotional Functioning 
scores (£(125) = -0.32, p > 0.05). In other words, there was no difference in the 
Physical Functioning scores of participants who were diagnosed with ABSD (TR) 
and participants who were diagnosed with ADSD (TR). A summary of the 
independent samples t-test is presented in Table 5. 
Table 5 
T-test of Social-Emotional Functioning Scores 
Test Value 
Levene's Test F = 0.896 
Levene's Test Significance p = 0.346 
t-test t = -0.318* 
t-test Significance p = 0.125 
Standard Error Difference 4.82918 
Note: See Appendix D for SPSS Output. Sample size: ABSD (TR) (n = 41); ADSD (TR) (n = 86). 
Mean V-RQOL by Type: (ABSD (TR) = 47.1037); (ADSD (TR) = 45.5669). *df= 125. 
The third question asked in this study was whether the demographic 
characteristics (duration, age, side effect, severity, and gender) of the 
participants significantly predict the QOL as measured by the V-RQOL to a 
statistical significance. It was hypothesized that the demographic characteristics 
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would significantly predict the QOL of the participant. To determine if any of the 
demographic characteristics significantly predicted the QOL a stepwise 
regression method was conducted. The stepwise regression procedure was 
conducted for participants who were receiving Botox and were ABSD (TR) and 
ADSD (TR). Prior to the stepwise regression analysis, the correlation between 
the independent variables is presented in Table 6. There was a significant 
positive correlation between the duration and QOL of the participants (r= 0.21, p 
< 0.05). There was also a significant positive correlation between the age and 
QOL of the participants (r= 0.27, p < 0.05). In other words, when the duration or 
age of the participant increased, the QOL score of the participant increased. 
Table 6 
Pearson's Correlations from Regression Analysis 
Variable Pearson's Correlation Significance (One tailed) 
Duration 0.212 0.040 
Age 0.272 0.012 
Side Effect -0.052 0.335 
Severity -0.031 0.399 
Gender 0.111 0.182 
Note: Correlations were conducted between the independent variables and QOL. 
The results of the stepwise regression procedure showed that there was 
only one independent variable that significantly predicted the QOL of the 
participant. This variable was the age of the participant (p < 0.05). In fact, the 
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model predicted that for every year increase in the participants age the QOL 
increased by 0.52 (B) units. In other words, when the age of the participant 
increased, the QOL increased as well. A summary of the stepwise regression 
model is presented in Table 7. 
Table 7 
Model Summary of Regression Analysis 
Test Value 
Model 
R 
R Square 
Adjusted R Square 
St. Error of the Estimate 
R Square Change 
F Change 
df\ 
dfl 
Sig. F Change 
Durbin-Watson 
1 
0.272 (Age) 
0.074 
0.060 
23.24037 
0.074 
5.366 
1 
67 
0.024 
2.236 
Note: See Appendix D for SPSS Output. Predictors (Constant): Age; Excluded Variables: 
Duration, Severity, Side Effect, and Gender. 
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The fourth question asked in this study was whether there was a 
statistically significant difference in QOL as measured by the V-RQOL for 
MixedSD (TR), ABSDTR, and ADSDTR versus ABSD and ADSD. It was 
hypothesized that there would be a significant difference between the two groups 
of participants. To determine if a significant difference existed between MixedSD 
(TR), ABSDTR, and ADSDTR versus ABSD and ADSD, an independent samples 
t-test was conducted analyzing the dependent variable QOL by type of SD. The 
findings for the Levene's test of equality of variances found that variances from 
each group were significantly different from one another (p < 0.05). Therefore, 
equality of variances was not assumed for the two groups. The results of the 
independent samples t-test showed that there was a significant difference 
between participants who had ABSD and ADSD compared to participants with 
MixedSD (TR), ABSDTR, and ADSDTR, in terms of their QOL (f(177.7) = 2.50, p 
< 0.05). In other words, participants who were diagnosed with ABSD and ADSD 
had significantly higher QOL when compared to participants who were diagnosed 
with MixedSD (TR), ABSTR, and ADSDTR. A summary of the independent 
samples t-test is presented in Table 8. 
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Table 8 
T-Test of MixedSD (TR), ABSDTR, and ADSDTR versus ABSD and ADSD 
Test Value 
Levene's Test F = 5.582 
Levene's Test Significance p = 0.019 
t-test f= 2.501* 
t-test Significance p = 0.013 
t-test Significance (one-tail) p = 0.0065 
Standard Error Difference 2.91165 
Note: See Appendix E for SPSS Output (Equal Variances Not Assumed). Sample size: 
ABSD/ADSD (n = 157); MixedSD (TR), ABSDTR and ADSDTR {n = 73). Mean V-RQOL by Type: 
(ABSD/ADSD = 43.1051); (MixedSD (TR), ABSDTR, ADSDTR = 35.8219). *df= 177.719. 
The fifth question asked in this study was whether there was a statistically 
significant difference in QOL as measured by the V-RQOL for MixedSD (TR), 
ABSDTR, and ADSDTR versus ABSD and ADSD without Botox. It was 
hypothesized that there would be a significant difference between the two groups 
of participants. To determine if a significant difference existed between MixedSD 
(TR) ABSDTR, and ADSDTR versus ABSD and ADSD without Botox, an 
independent samples t-test was conducted analyzing the dependent variable 
QOL by type of SD. The findings for the Levene's test of equality of variances 
found that variances from each group were significantly different from one 
another (p < 0.05). Therefore, equality of variances was not assumed for the two 
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groups. The results of the independent samples t-test showed that there was not 
a significant difference between participants who had ABSD and ADSD 
compared to participants with MixedSD (TR), ABSDTR, and ADSDTR without 
Botox, in terms of their QOL (f(65.3) = 1.00, p > 0.05). In other words, 
participants who were diagnosed with ABSD and ADSD without Botox did not 
have significantly different QOL when compared to participants who were 
diagnosed with MixedSD (TR), ADSDTR, and ADSDTR without Botox. A 
summary of the independent samples t-test is presented in Table 9. 
Table 9 
T-Test of MixedSD (TR), ABSDTR, and ADSDTR versus ABSD and ADSD-No 
Botox 
Test Value 
Levene'sTest F = 5.415 
Levene's Test Significance p = 0.022 
t-test t = .996* 
t-test Significance p = 0.323 
t-test Significance (one-tail) p = 0.1615 
Standard Error Difference 4.09819 
Note: See Appendix E for SPSS Output (Equal Variances Not Assumed). Sample size: 
ABSD/ADSD (n = 97); MixedSD (TR), ABSDTR, ADSDTR (n = 29). Mean V-RQOL by Type: 
(ABSD/ADSD = 43.7371); (MixedSD (TR), ABSDTR, ADSDTR = 39.6552). *df= 65.319. 
The sixth question asked in this study was whether there was a 
statistically significant difference in QOL as measured by the V-RQOL for 
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MixedSD (TR), ABSDTR, and ADSDTR compared to ABSD and ADSD with 
Botox. It was hypothesized that there would be a significant difference between 
the two groups of participants. To determine if a significant difference existed 
between MixedSD (TR), ABSDTR, and ADSDTR types compared to ABSD and 
ADSD with Botox, an independent samples t-test was conducted analyzing the 
dependent variable QOL by type of SD. The findings for the Levene's test of 
equality of variances found that variances from each group were not significantly 
different from one another (p = 0.28). Therefore, equality of variances was 
assumed for the two groups. The results of the independent samples t-test 
showed that there was a significant difference between participants who had 
ABSD and ADSD compared to participants with MixedSD (TR), ABSDTR, and 
ADSDTR in terms of their QOL (f(142) = 2.60, p < 0.05). In other words, 
participants who were diagnosed with ABSD and ADSD with Botox did have 
significantly different QOL when compared to participants who were diagnosed 
with MixedSD (TR), ABSDTR, and ADSDTR. In fact, those who were diagnosed 
with ABSD and ADSD had higher QOL than participants who were diagnosed 
with MixedSD (TR), ABSDTR, and ADSDTR with Botox. A summary of the 
independent samples t-test is presented in Table 10. 
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Table 10 
T-Test ofMixedSD (TR), ABSDTR, and ADSDTR Compared to ABSD andADSD 
-Botox 
Test Value 
Levene's Test F = 1.194 
Levene's Test Significance p = 0.276 
t-test t = 2.603* 
t-test Significance p = 0.010 
t-test Significance (one-tail) p = 0.005 
Standard Error Difference 4.03884 
Note: See Appendix E for SPSS Output (Equal Variances Not Assumed). Sample size: 
ABSD/ADSD (n = 103); MixedSd (TR), ABSDTR, ADSDTR (n = 41). Mean V-RQOL by Type: 
(ABSD/ADSD = 45.1456); (MixedSd (TR), ABSDTR, ADSDTR = 34.6341). *df= 142. 
The seventh and final question asked in this study was whether there was 
a statistically significant difference in QOL as measured by the V-RQOL for 
ABSD versus ADSD with Botox. It was hypothesized that there would be a 
significant difference between the two groups of participants. To determine if a 
significant difference existed between ABSD versus ADSD with Botox, an 
independent samples t-test was conducted analyzing the dependent variable 
QOL by type of SD. The findings for the Levene's test of equality of variances 
found that variances from each group were not significantly different from one 
another (p = 0.77). Therefore, equality of variances was assumed for the two 
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groups. The results of the independent samples t-test showed that there was not 
a significant difference between participants who had ABSD compared to 
participants who had ADSD in terms of their QOL (f(101) = .28, p > 0.05). In 
other words, participants who were diagnosed with ABSD did not have 
significantly different QOL when compared to participants who were diagnosed 
with ADSD. A summary of the independent samples t-test is presented in Table 
11. 
Table 11 
T-test of ABSD versus ADSD with Botox 
Test Value 
Levene's Test F = .083 
Levene's Test Significance 
t-test 
t-test Significance 
t-test Significance (one-tail) 
Standard Error Difference 
Note: See Appendix E for SPSS Output (Equal Variances Not Assumed). Sample size: ABSD (n 
= 33); ADSD (n = 70). Mean V-RQOL by Type: (ABSD = 46.0606); (ADSD = 44.7143). *df= 101. 
p = 
t = 
P : 
p = 
0..774 
.277* 
= .782 
: 0.391 
4.85627 
Chapter Summary 
This chapter has focused on describing the results of data collection and 
statistical analysis. The null hypothesis was supported in the initial hypothesis 
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test, and there was no significant difference between V-RQOL scores for ABSD 
(TR) and ADSD (TR), or in later post-hoc testing for the Physical Effects and 
Social-Emotional subscales. 
Other ancillary variables were then analyzed to assess their affect on V-
RQOL scores, and significant findings with the available variables and data of 
side effects, severity, age, duration and gender were noted. Age was singled out 
by step-wise regression analysis as the significant variable, but the correlation 
was weak. 
Then, a renewed look at the entire sample was conducted. A significant 
difference in V-RQOL mean score was found between those with MixedSD (TR), 
ADSDTR, and ADSDTR versus those with ABSD and ADSD. No significant 
difference was found in these same groups utilizing only those who were not 
receiving Botox. A significant difference was found in these groups when only 
those receiving Botox treatment were utilized. And finally, ABSD respondents 
were tested against ADSD respondents controlling for Botox use, and no 
significant difference was found in V-RQOL score. 
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CHAPTER 5 
Discussion 
This chapter presents an analysis of the data presented in chapter 4 with 
regard to the research questions that guided this study. The conclusions are 
reviewed in the context of existing research on the topics of SD and QOL. First, 
an introduction reviews the prominent features associated with this study and 
similar previous research. Next, the research questions are presented 
sequentially, followed by the limitations, implications for practice, and 
recommendations of the study. 
The communication difficulties caused by SD can significantly affect 
speaking ability and comfort, psychological and emotional well being, and social 
functioning and professional effectiveness (Baylor et al., 2005). The most recent 
research indicates that the etiology of SD consists of a dysfunction of the neural 
networks of the cortex in the brain, as well as the associated neural networks of 
the sub-cortex in the brainstem (Simonyan et al., 2008). Although some types of 
surgery hold significant promise (Berke et al., 1999; Koufman et al., 2006; 
Ramacle et al., 2004), the current best practice treatment for SD is injection with 
Botox into key vocal chord muscles (Blitzer et al., 1998; Boutsen et al., 2002; 
Watts et al., 2005). However, despite the considerable body of knowledge and 
treatment skill that has amassed regarding this condition, it is evident that many 
people with SD still struggle with their QOL, based on the results of this study. 
Many studies have shown that, in the short term at least, Botox treatment 
improves QOL for those with ADSD (U) (Benninger et al., 2001; Bhattacharyya & 
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Tarsi, 2001; Courey et al., 2000; Hogikyan et al., 2001; Rubin et al., 2004). 
However, research among the other simple type, ABSD (U), as well as MixedSD 
(U), is sparse, due to the small number of patients who appear in clinics with 
these types (Blitzer & Brin, 1991; Adler et al., 1997; Tisch et al., 2003). 
Hogikyan et al. (2001) measured positive QOL changes in a longitudinal 
study for the first six injections of Botox treatment. In addition, under ideal 
circumstances the positive effect of Botox lasts 4.42 months (Tisch et al., 2003). 
Multiplying six treatments by 4.42 months would equal 26.52 months, or 2 years 
and 2.5 months, not counting wait time to set up appointments. This highlights a 
limitation of the research base, because the current study found that respondents 
had been having symptoms of SD for an average of 11.03 years, long past the 
sixth injection mark. 
According to Feeley (2008), 65% of respondents with SD thought that 
Botox was most helpful in alleviating symptoms. The next closest choice was 
speech therapy at 18.5%. Recent research indicates that Botox and speech 
therapy make an effective combination (Murry & Woodson, 1995). Surgery, a 
treatment that has helped many, was only chosen by 6.2% of a sample of 758 
respondents as most helpful in alleviating symptoms. It is important to note that 
35% of the respondents did not choose Botox as most helpful at alleviating 
symptoms (Feeley). This means that one third of the respondents in that study 
were not using the treatment of choice at the time of the survey. 
Several researchers have examined the reasons that Botox is not more 
effective. One issue noted in the research is that Botox is more effective for 
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ADSD (U) than for ABSD (U), based upon expert rating of voice (Blitzer et al., 
1998; Tisch et al., 2003). Specifically, Blitzer et al., found that ADSD (U) patients 
had a return to 90% of normal voice lasting an average of 15.1 weeks, while 
ABSD (U) patients had an average improvement to 66.7% of normal voice with 
an average duration of 10.5 weeks. Expert rating of voice can include 
quantitative voice analysis, otolaryngological assessment, or computerized 
speech software. As stated above, ADSD (U) improves significantly when treated 
with Botox, although the effect much beyond 2 years of treatment in general is 
not known. QOL is measured by a voice related QOL scale, such as the V-RQOL 
instrument used in this study. Persons with SD respond to the scale based on 
their own internal subjective perception. 
This study attempted to apply the logic that if ADSD (U) can be more 
easily treated with Botox, and a better result can be obtained with ADSD (U), 
then QOL scores should be significantly higher for ADSD (TR) than ABSDl(TR) 
when measured in aggregate. Based upon the dearth of ABSD (U) subjects in 
previous studies, a high sample volume was needed in order to evaluate this 
difference. The NSDA sampling frame was used in order to obtain a sufficient 
amount of survey respondents. 
Conclusions and Interpretation of Findings 
This section presents the relevant data of the study with regard to the 
research questions and in the context of existing literature on the topics of SD 
and QOL. Each research question will be presented sequentially. Following the 
analysis, the implications of these findings are discussed. 
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Research question 1 asked if there is a statistically significant difference in 
QOL as measured by the V-RQOL for ABSD (TR) and ADSD (TR) for those 
receiving Botox treatment. The result of the analysis of ADSD (TR) compared to 
ABSD (TR) respondents currently receiving Botox treatment was first tested by 
including persons with an associated TR in order to increase the sample size. 
Analysis showed that there was no difference in the QOL of participants, (those 
currently receiving Botox treatment), who were diagnosed with ABSD (TR) and 
those who were diagnosed with ADSD (TR). 
Clinical observation has indicated that ADSD is more effectively treated 
with Botox than ABSD based on expert-rated assessments (Blitzer et al., 1998; 
Boutsen et al., 2002; Tisch et al., 2003). Specifically, Blitzer et al. contended that 
ADSD patients had a return to 90% of normal voice lasting an average of 15.1 
weeks. On the other hand, ABSD patients had an average improvement to 
66.7% of normal voice with an average duration of 10.5 weeks. However, the 
results of the present study do not support the theory that the findings of Blitzer 
et al., Boutsen et al., and Tisch et al. should correlate with QOL ratings because 
participants with ABSD (TR) and those with ADSD (TR) had no significant 
differences in QOL when their respective types of SD were treated with Botox. 
The results of this study suggested that Botox treatment is not more effective for 
patients with ABSD (TR) than for patients with ADSD (TR) based upon patient 
perception of QOL rather than expert ratings of treatment effectiveness and voice 
improvement. 
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Research question 2 asked if there is a statistically significant difference in 
QOL as measured by the V-RQOL subscale scores of Physical Functioning or 
Social-Emotional Functioning for ABSD (TR) and ADSD (TR) for those receiving 
Botox treatment. The analysis of the data showed that there was no difference in 
the V-RQOL subscales of Physical Functioning and Social-Emotional Functioning 
of participants who were diagnosed with ABSD (TR) and participants who were 
diagnosed with ADSD (TR). This did not support the theory that significance 
might exist in one domain and not the other. 
Hogikyan et al. (2001) suggested that SD could have significant effects on 
one's QOL in terms of not only physical difficulty but also the functional aspects 
of social and professional life, as well as psychological and emotional effects on 
the person. The results of this study indicate that QOL with regard to Physical 
Functioning and Social-Emotional Functioning may operate systemically, and 
thus Botox treatment perhaps addresses both simultaneously. Researchers have 
emphasized identifying and dealing with psychosocial problems as a key factor in 
maintaining the health of persons with a chronic illness (Sherboume et al., 1992). 
In the context of Sherboume et al.'s finding, the results of this study suggest that 
Botox may play an important role in addressing psychosocial problems by 
addressing physical symptoms simultaneously. 
Research question 3 asked if the demographic characteristics (duration, 
age, side effect, severity, and gender) of the participants predict QOL as 
measured by the V-RQOL to a statistical significance. The analysis of the data 
showed that there was a weak but statistically significant positive correlation 
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between the age of the participant and QOL score. Wingate et al. (2005) had 
found that there was no statistically significant improvement in QOL for those 
receiving Botox over 65 years of age. In this study, age does have weak positive 
correlation with QOL. This apparent contradiction in result between this study 
and the Wingate study may be due to side effect, which had been mentioned as 
a possible confounding factor by Wingate et al.. The results of the present study 
suggested that side effect is not a confounding factor for the QOL of ABSD (TR) 
and ADSD (TR) participants. However, Wingate et al.'s sample size from that 
study was small (n = 13), and all subjects were 65 years of age or over. The 
sample size for this part of the current study was much larger (n=69), which may 
have smoothed the confounding factors of side effect, which Wingate et al. noted 
may have skewed their result. 
Research question 4 asked if there is a statistically significant difference in 
QOL as measured by the V-RQOL for MixedSD (TR), ADSDTR, and ABSDTR 
versus ABSD and ADSD. The results of the analysis suggested that participants 
who were diagnosed with ABSD and ADSD had significantly higher QOL mean 
scores when compared to participants who were diagnosed with MixedSD (TR), 
ADSDTR, and ABSDTR. During a consultation with Dr. Patrick Reidy, a Naples, 
Florida Ear, Nose, and Throat specialist who does Botox injections for SD, he 
indicated that the factor most difficult to treat in his experience was TR (personal 
communication, 8/28/2008). The results of this study support Dr Reidy's 
assertion, and suggested that the addition of TR or MixedSD significantly 
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decreases QOL as compared to the QOL of persons who suffer from simple 
ABSD or ADSD. Research questions 5 and 6 further investigated these results. 
Research question 5 asked if there is a statistically significant difference in 
QOL as measured by the V-RQOL for MixedSD (TR), ADSDTR, and ABSDTR 
versus ABSD and ADSD without Botox. The results of the data analysis indicated 
that participants who were diagnosed with ABSD and ADSD without Botox did 
not have significantly different QOL when compared to participants who were 
diagnosed with MixedSD (TR), ABSDTR and ADSDTR. This suggests that 
participants with any type of SD who are not receiving Botox treatment will have 
similar QOL scores. When taking into account the conclusions of research 
question 4 which showed a significant difference between the types, the logical 
next step, research question 6, provides a comparison of QOL differences 
between SD types receiving Botox treatment. 
Researchiquestion 6, then, asked if there is a statistically significant 
difference in QOL as measured by the V-RQOL for MixedSD (TR), ADSDTR, and 
ABSDTR compared to ABSD and ADSD who are receiving Botox treatment. The 
results of the data analysis indicate that participants who were diagnosed with 
only ABSD or ADSD had higher QOL than participants who were diagnosed with 
MixedSD (TR), ADSDTR, and ABSDTR with Botox. Again, Dr. Reidy's comment 
is supported by the results, in that the addition of TR appears to be a significant 
detractor to quality of life among persons living with SD. However, a caveat here 
is that the MixedSD group, included with all tremor respondents, did contain 
respondents without tremor. 
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Last, research question 7 asked if there is a statistically significant 
difference in QOL as measured by the V-RQOL for ABSD versus ADSD 
receiving Botox treatment. TR was removed from the initial research question 
based upon findings of research question 6. The results of the study indicate that 
participants who were diagnosed with ABSD and treated with Botox did not have 
significantly different QOL when compared to participants who were diagnosed 
with ADSD who were treated with Botox. This would suggest that the findings 
reported by Blitzer et al. (1998), Boutsen et al. (2002), and Tisch et al. (2003) 
point to serious differences between expert evaluation of treatment success and 
patient perception of QOL. Their studies suggested that Botox injection worked 
more effectively for those with ADSD than it did for those with ABSD, although 
their studies did not take into account the possibility of TR influencing the data. 
Another conclusion could be that self-report measures of QOL are not directly 
and positively correlated with expert analysis. The following paragraphs attempt 
to cast the individual conclusions of the research questions in a more connected 
and contextual light. 
The logic behind the study hypotheses stemmed from the fact that clinical 
observation has indicated that ADSD is more effectively treated with Botox than 
ABSD based on expert-rated assessments (Blitzer et al., 1998; Boutsen et al., 
2002; Tisch et al., 2003). Not only is there a clinically observable effect, but there 
is also a clear correlation between initiation of Botox treatment and increased 
QOL scores on Voice Related QOL scales (Benninger et al., 2001; 
Bhattacharyya & Tarsi, 2001; Courey et al., 2000; Hogikyan et al., 2001; Rubin et 
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al., 2004). At first, it might appear that QOL is better if treatment is better. 
However, all that is established in these results is that QOL scores improve with 
Botox treatment over the short term, and that there is a clinically observable 
positive, if temporary, difference in voice quality, which is better and longer in 
duration for ADSD than for ABSD. 
The key difference between clinical observation and Voice Related QOL 
Scales is that clinical observations of voice quality are external, and the scales 
rely on internal perception of QOL, which usually includes voice quality but also 
extends into other domains of life. Thus, many variables are at play in an internal 
and personal evaluation of QOL, as compared to clinical evaluation of voice 
quality alone. In one study of chiropractic treatment for SD, for example, 
improvement on a QOL scale did not match clinical observation of voice, which 
did not note these same improvements (Lee et al., 2003). Deary et al. (2003) 
contended that personal perception of voice correlated with, professional 
evaluation of that same voice. However, while correlation between self-rating and 
expert rating were significant in that study (r= 0.20, r (squared) = 0.04, p < 0.05), 
this is still a weak correlation. 
As discussed earlier, QOL is generally evaluated on voice related domains 
of physical, emotional, and social functioning. One conjecture was that the 
Physical Functioning or Social-Emotional Functioning V-RQOL subscales might 
separate out differences in QOL. As part of the post-hoc analysis, the subscales 
were not significantly different. In addition, while V-RQOL improvement can be 
dramatic after a first injection with Botox (up to 60 V-RQOL total score points), 
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the improvement begins to level off, though still improved, by the third injection. It 
would be important to know what happens over time longitudinally to V-RQOL 
scores of patients receiving Botox beyond six injections, the limit to the Hogikyan 
et al., (2001) study. Because the average duration of SD symptoms for the study 
participants was 11.03 years, it would be reasonable to assume that many study 
participants would have had many more than six injections. This duration finding 
also points out possible differences between patient samples in the clinical 
environment and the NSDA sample. This duration variable of this sample may be 
significantly different from that of patients who first visit a voice clinic and then 
are studied over the next year or two. 
Another difference between this study and previous studies has to do with 
the diagnostic mix of the sample. Most studies, as indicated earlier, have used 
only ADSD (U) patients due to sampling issues. In addition, numbers reported by 
large clinics appear quite different from those in the NSDA sample. In combining 
the aggregate data of Blitzer and Brin (1991) and Adler et al. (1997), out of 521 
patients, 61 (11.7%) were ABSD (U). No mention is made of MixedSD (U). Tisch 
et al. (2003) noted the following: 89% ADSD, 1.8% ABSD, and 4.7% mixed 
diagnosis. 
When we compare these numbers to the NSDA sample, there is a stark 
difference. Out of a total response count of 258 for the question, 108 simple 
ADSD were recorded (41.9%), and 66 ABSD responses were recorded (25.6%). 
This contrasts with the 11.7% incidence of ABSD (U) noted above. Even more of 
a contrast, the MixedSD (TR) provided different frequency compared to the 
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previous studies. Twenty-four respondents (9.3%) reported ADSDTR, 17 (6.6%) 
reported ABSDTR, 30 (11.6%) reported MixedSD, and 13 (5.0%) noted having 
MixedSDTR. Between the MixedSD (TR) types alone, this accounted for 16.6% 
of responses alone, compared with the 4.7% noted by Tisch et al. (2003). 
Limitations 
One limitation of this study was the sample size. In hindsight, the first 
analysis in the logical chain could have been of simple ABSD and ADSD to 
ABSDTR and ADSDTR. However, while there were 17 ABSDTR and 24 
ADSDTR in the original sample, there were only 24 in aggregate left once those 
who were not receiving Botox and those who did not finish the V-RQOL were 
removed. This number was insufficient for analysis compared to simple ABSD 
and ADSD. For purposes of this study, however, it would be important to note 
that removal of those with TR did not change the result of the ABSD and ADSD 
QOL comparison. 
Use of the V-RQOL appeared to strengthen the study methodology; 
however, question number seven of the V-RQOL asks the respondent to 
evaluate the following statement: "I have trouble doing my job or practicing my 
profession because of my voice" (see Appendix C). Ten respondents with an 
average age of 64.9 years who were being treated with Botox did not answer 
question seven and thus were removed from the calculation. Those who were 
either retired or otherwise not working may have elected to skip the question, 
which might have skewed the result in the direction of higher QOL scores, based 
on the Wingate et al. (2005) study. 
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This potential skew of the regression analysis might also have affected the 
variables of age and duration, which were the two highest correlations when 
calculated against QOL. This study was also limited because the quantitative 
design did not allow for data to be collected on participant reconciliation to their 
SD conditions, which would be necessary to examine duration more extensively. 
For example, it would help to know where in the Psychological Cascade process 
proposed by de Jong et al. (2003) that the respondent was at the time of the 
survey. 
Another limitation is that respondents chose their own medical diagnosis 
and severity level on the survey instrument; there was no expert evaluation 
involved to provide consistency across all participant responses. Because most 
respondents probably did not have medical training, they may not have had 
enough knowledge to correctly understand what they were told by their 
physician. In addition, another limitation inherent in this methodology is that there 
was no guarantee that a respondent was prevented from taking the survey more 
than once. 
Another limitation may have been the detail of the questions asked on the 
survey instrument. The addition of extra data categories may have deepened the 
analysis. For example, if the amount of times that the respondent had been 
treated with Botox had been included, then this variable could have been added 
to the analysis. As it was, although the respondent indicated that they were 
currently being treated with Botox, it was not known how many times. Hogikyan 
et al. (2001) found that, while QOL scores at subsequent treatments were still 
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better than before the first treatment, they were lower than after the first injection. 
A longitudinal survey might have helped tease out confounding variables. In 
addition, the desire in survey development to keep the survey instrument burden 
low may have worked against the best analysis of variables by limiting the 
number of variables that were included. 
Last, while not necessarily a weakness in itself, the constitution of the 
sample was quite a bit different from that of samples reported by previous clinic 
studies. For example, as discussed in chapter 4, this study had a much higher 
proportion of ABSD (TR) to ADSD (TR) than the previous studies. This can be a 
limitation in attempting to compare the study to previous ones with a different 
sample constitution. 
Thus, there are certain limitations to the conclusions that can be drawn 
from this study. However, the large sample size and high numbers of reportedly 
rare types do allow for certain conclusions. Still, it would have been helpful to 
verify accuracy of respondent information, and to encourage respondents to 
answer all questions in order to increase sample size. The inclusion of more 
questions regarding possible confounding variables would have increased the 
breadth of analysis. These issues will need to be accounted for in future survey 
research with this population. 
Implications of the Study to Practice 
The conclusions section discussed the analysis of data collected from 
respondents with SD who are members of the NSDA. For those with SD, the 
current best practice treatment (Botox injection) often provides significant relief of 
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symptoms; however, the treatment is temporary, has side effects that affect voice 
negatively, and provides variable results as judged by professional observers. A 
variation in result has been specifically found in the treatment of ABSD (U) as 
compared to ADSD (U). Botox treatment for ADSD is observably better in both 
length of positive effect and improvement of voice. This study asked the question 
of whether that difference in observable improvement translated into significant 
differences in QOL between the two types of SD. The implications of the 
conclusions of the study reviewed below should be interpreted in the context of 
how medical professionals need to look beyond patient self-perceptions of 
general QOL to individual considerations to how participants feel Botox affects 
their specific diagnoses and why. 
The sample size was adequate for the analysis. From this sample, it is 
clear that there is not a significant difference in personal perception of QOL 
between ABSD and ABSD respondents currently receiving Botox. The logical 
chain that begins at observable expert differences in treatment effectiveness 
does not end with positively correlated differences in perceived QOL. Therefore, 
this implies that some other unknown set of factors come into play to explain the 
non-significant relationship between treatment differences and QOL. 
As one possibility, self-rated assessment of voice correlated weakly with 
expert-rated assessments in one study (Deary et al., 2003). If this relationship 
holds for self-perception of QOL compared with expert-rating of voice, then 
observable differences in treatment effectiveness are not necessarily significantly 
correlated with self-perception of QOL. Recent qualitative research conducted by 
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Baylor et al. (2007) suggested that a missing piece might be the intricacy of how 
Botox treatment influences each patient individually. Each patient makes their 
own meaning of the success and failure of their Botox treatment based on 
treatment factors and how these specifically influence the physical, 
psychological, and social areas of their unique life. This implies that the V-RQOL 
instrument used in this study and others may be unable to pose questions with 
the necessary level of subjectivity and detail to accurately assess how much 
Botox treatment, (and other treatments), improves the quality of life for persons 
living with SD. More specific QOL scaling would help in the clinical assessment 
of individual QOL challenges. 
For example, although observable results of Botox injection for a grade 
school teacher might be excellent, there might be trouble making a clinic 
appointment for Botox injection before the beginning of each semester. That 
teacher's evaluation of QOL might suffer dueito the need to struggle with a less 
optimal voice at the beginning of the semester, which is an important time to 
make impressions on the class. According to Baylor et al. (2007), treatment 
discomfort varies between individuals. As another example, then, apprehension 
about the medical injection procedure itself might reduce QOL perceptions. This 
concept of treatment burden might be more difficult for abductor than adductor 
patients because of the increased difficulty of locating the Botox injection 
effectively, increasing discomfort during injection (Patrick Reidy, M.D., Personal 
Communication, 9/4/2008). Yet another illustration of the point concerns the drop 
in V-RQOL scores over time noted by Hogikyan et al. (2001) from the first 
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injection to the sixth. Perceptions about QOL can change after the second and 
subsequent injections, even if they remain more favorable than before the first 
injection. 
The results of this study suggested that Botox injection significantly 
improves QOL ABSD and ADSD patients as compared to a group consisting of 
all other types. This implies that Botox injection is a reliable way to treat SD, and 
may be a strong foundation for other types of SD treatment. Murry and Woodson 
(1995) and Silverman et al. (2006) pointed to another dynamic: change in speech 
behavior after Botox injection. Speech therapy after Botox can almost double the 
length of Botox effectiveness, focusing on compensatory speech behaviors and 
musculoskeletal tension. The dynamic behind this needs further investigation. It 
is possible, for example that this change in behaviors can be extended as well. 
Perhaps neurophysiological training using thorough assessment and biofeedback 
techniques might enhance the speech behavior changes observed in speech 
therapy after Botox injection. The Sircle technique, discussed in the literature 
review, is one innovative example of neurophysiological retraining. It does not 
appear that this technique has been specifically studied with SD. Adding weight 
to this idea, Maryn et al. (2006) found that biofeedback applied to other types of 
dysphonia often showed success in the form of improved vocal symptoms. They 
key here is intervene to change vocal behaviors and neuromuscular patterns 
after Botox injection, not before. 
Recommendations for Future Research 
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Perhaps the most compelling finding in this study came from post-hoc 
testing used to explain the result of the initial hypothesis. The group of SD 
respondents diagnosed with MixedSD (TR), ADSDTR, and ABSDTR had 
significantly lower V-RQOL scores than simple ABSD and ADSD respondents 
combined, controlled by inclusion of only those currently receiving Botox 
treatment. This relationship will need further definition. It is possible that the key 
variable is the inclusion of TR, which is not effectively treated with Botox; it is 
also possible that the key variable is the MixedSD diagnosis, which might create 
more difficulty in treatment. Conversely, the key variable might be as yet 
unnamed or may be a combination of factors. 
In addition, much more needs to be known about the variables that 
contribute to QOL. Certainly, Botox treatment is the primary variable affecting 
QOL that is known at this time, either on its own or in concert with focused 
speech therapy,;This study did not determine how long the respondent had been 
using Botox, just that they were using it at the time of survey completion. More 
work needs to be done with longitudinal studies of QOL and Botox use over 
longer periods of time, both with and without focused speech therapy, or using 
other types of neuromuscular retraining. It would be important to note here that 
research continues into the key area of Botox injection method, in order to 
increase benefitand reduce side effects (Beilamowicz et al., 2002). However, 
more studies are needed in this regard with the types that show up more rarely to 
the clinic, such as ABSD or a particular type with TR. The preponderance of 
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research has been done on the type of SD that responds best to Botox (ADSD 
(U)). 
We might assume that our survey respondent size was large enough that 
the ABSD (TR) comparison to ADSD (TR) QOL was not muted or amplified by a 
skewed sample. Thus, this result can begin to shift the perspective first taken in 
this study. It is intriguing that despite the additional treatment burden and 
decreased effectiveness of Botox treatment for ABSD, respondents with ABSD 
and ADSD make meaning of their QOL in roughly the same way. This leads to 
the question of how those who score higher on the V-RQOL make meaning out 
of their life with SD. There would be a mix of internal psychological factors that 
could be studied in order to form a template of the thoughts, emotions, and 
behaviors of someone who copes well with SD. One possible confounding factor 
in this regard that was not studied involved the participation of the respondent in 
support groups, either in person or online. The NSDA membership has access to 
this kind of support. The qualitative work of Baylor et al. (2005) and Baylor et al. 
(2007) deepened the field's understanding of individual and subjective factors 
within the physical, psychological, and social domains of QOL. One effective 
method would be to alternate qualitative studies with quantitative studies utilizing 
larger sample sizes based on the qualitative findings. This methodology might 
expose more factors that affect QOL. It also might help direct the content of 
future scales designed to tap into individual differences in perception and needs. 
A statistically significant finding existed between MixedSD (TR), ABSDTR, 
and ADSDTR versus the simple ABSD plus the ADSD types receiving Botox 
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treatment. However, when Botox was removed as a variable, the result became 
not significant. This relationship needs further exploration in order to tease out 
the exact meaning of these findings. At this point, it is unknown if the variable of 
added TR might be the significant variable in QOL with Botox treatment, or if it is 
the MixedSD type itself that is the key. The combination of ABSDTR and 
ADSDTR who receive Botox drops down to 14 in this dataset, making 
comparison of those with TR to those without difficult. Thus, as Wingate et al. 
(2005) found, a small sample like this left the result vulnerable to confounding 
variables. However, some factor within the types of SD diagnoses does appear 
to be related to QOL perception. Further work with a larger data sample might 
tease out this relationship. 
Maija and Uchino (2008) reviewed the current state of research on social 
support, and found a relationship between social and emotional support and 
health. Sherbourne et al. (1992) found that social support increased the physical 
health and emotional well being of chronically ill people. Barry (2000) noted that 
in a regression analysis of factors related to chronic illness and social support, 
that social support is related to emotional functioning but not to physical 
functioning. Futrovsky (1992) found that the number of social supports that a 
person with SD had correlated with social adjustment, a construct which might 
form a significant part of QOL. A future study could examine the NSDA sampling 
frame and analyze support group membership QOL compared to those who are 
not in a support group. In order to understand the implications of social support, 
the V-RQOL or other instrument that has a Physical subscale and a Social-
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Emotional subscale could be used. If the previous findings hold true, then further 
factors related to the cognitive-emotional-behavioral template mentioned in the 
last paragraph could be studied further. In addition, because only 6.3% of the 
NSDA membership attends a support group, and only 6.2% participate in online 
SD forums, demonstrated positive result from support group membership could 
help increase membership (Feeley, 2008). 
One of the crucial functions of a support group could be to facilitate the 
emotional acceptance of the persistent voice problems associated with SD 
through awareness of the grief reaction. De Jong et al. (2003) contended that 
perhaps the futile emotional struggle involved with not accepting a voice disorder 
becomes problematic. In describing the Psychological Cascade Model of 
recovery from chronic illness, they noted from their study of 76 teachers with 
chronic, persistent voice problems that most (71%) were stuck in Stage one, 
when the person with the voice disorder experiences the illness as a threat. 
Subjects at this stage had more inadequate coping strategies and more serious 
voice complaints. 
Stage two, reached by only 16%, is called the Pit. This is characterized by 
surrender to the loss. Surrender in this case is has a positive connotation, where 
the illness is accepted and incorporated into one's life view, without necessarily 
giving in to it. Much of the depression, anxiety, and other undesirable 
psychological states ease significantly in this second phase. The third stage is 
characterized by renewal and recovery. This third stage goes beyond acceptance 
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to a new life that accepts the limitations imposed by the voice disorder, yet seeks 
to maximize opportunities and QOL. 
Although the variable of duration in this study showed only a weak 
correlation, perhaps specific groups of SD diagnoses that show the most 
persistent problems might show a higher correlation with low QOL in a future 
study. If so, any group with a high correlation with low QOL scores might be 
studied using the model and methodology presented by de Jong et al. in order to 
detect Psychological Cascade phase as matched against QOL score. Based on 
the results of this study, it would also be difficult to ignore age as a potential 
variable in how a person becomes reconciled to a lifelong physical problem like 
SD. 
Another research tactic might be to conduct domain specific research in 
order to understand the dynamics of the interaction of the person, SD, and that 
domain. For example, Feeley (2008) noted the majority of respondents felt that 
they had been discriminated against in some way in the work environment. The 
highest choice was being "viewed as weak" (14.9%), then "hiring difficulties" 
(12.3%) and "job loss" (12.3%). Social discrimination (9.8%) and "limited 
opportunities for promotions (7.7%) also figured prominently. Further studies 
should investigate how the variable of job discrimination may influence QOL 
perceptions in persons with SD. 
Alternatively, another domain specific research effort could center on the 
effect of SD on marital relationships in order to assess its effect on QOL. 
Measurement of marital satisfaction on a standardized scale such as the 
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ENRICH Marital Satisfaction Scale would provide a reliable, and valid measure of 
marital satisfaction with a low response burden at 15 items (Flowers & Olson, 
1993). Marital satisfaction scale scores of married persons with SD could be 
compared against a control group of married persons. 
Based upon the results of this study, it is also recommended that 
qualitative studies be performed with participant groups similar to those of this 
study in order to obtain more detailed information about how SD impacts QOL in 
a more open ended format. This study points out the need to discover more 
known factors that affect QOL. The value of such qualitative research would be 
that it takes a more post-modern view than this current study, and focuses on the 
unique internal experience of each person among many complicated 
relationships between the person, their life domains, and the treatment and its 
effects. In other words, merely noting that two patients in a clinic have achieved 
the same expert rating in voice improvement does not connect directly to a 
equivalent internal experiences about the result. When the dynamics of person, 
biopsychosocial domains, and treatment interactions are considered, the number 
of possible factors grows exponentially and appears to be best considered in 
each individual case or with small sample sizes (e.g., focus groups). 
Clinical studies of other alternative treatments to this point appear have 
attempted to cure the condition or improve SD symptoms as a primary treatment. , 
Another area of clinical study might be to attempt previously studied adjunct 
treatments in concert with Botox, rather than attempting to take on the full force 
of the spasms. For example, Roy et al. (1996) and Dromey et al. (2008) identified 
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the benefits of laryngeal massage with muscle tension dysphonia. It is possible 
that this might help with some of the same behaviors that speech therapy does, 
because the compensating speech behaviors of someone with SD are similar to 
the muscle tension disorder that laryngeal massage treats. 
Summary 
In summary, this study presents more questions than it answers. More 
needs to be known about the effectiveness of Botox injection with all types of 
diagnosis. Questions need to be answered about what happens to QOL over 
time under Botox treatment. The similar QOL scores between ABSD (TR) and 
ADSD (TR) respondents have implications in terms of expert measurements 
versus personal perception in physical, psychological, and social domains. Social 
support mechanisms and their role in improving QOL with SD need further study. 
Further study of adjunct treatments to Botox is another promising avenue of 
inquiry. While this study shows that expert assessment of vocal quality does not 
correlate with personal perception of QOL, the bridge between the two 
perceptions that would make them link logically is compelling. Perhaps most 
importantly from a psychological perspective, further study of how persons with 
SD make meaning of their QOL could provide a template of cognitive, emotional, 
and behavioral attitudes which lead to a higher personal evaluation of QOL. 
This study found the original null hypothesis to be true, that there is no 
difference in QOL between those with ABSD (TR) receiving Botox and those with 
ADSD (TR) receiving Botox. This finding highlights that there are factors other 
than degree of effectiveness of treatment that influence QOL. More research 
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needs to be done on the factors located in this gap between expert rating of 
treatment effectiveness and patient rating of life effectiveness. A bridge is 
needed to connect the inner world of the patient and the unique social 
environment they inhabit to the outer expert evaluation process. 
Although ABSD and ADSD QOL scores were not significantly different, 
these two types combined have a significantly higher QOL when compared 
against MixedSD (TR) in combination along with ABSDTR and ADSDTR, when 
treated for Botox. While not the origional focus of this study, this finding deserves 
further attention. Based upon the result above and the lack of information on 
treating MixedSD (TR), as well as ABSD (TR) and ADSD (TR), it is not known if 
the key variable in this case will prove to be treatment effectiveness with 
MixedSD (TR), and ABSD (TR) and ADSD (TR), or something else entirely. It is 
worthy of note that the two pure types have a higher mean QOL score than any 
other type. 
Perhaps most important, however, those factors in the gap for ABSD and 
ADSD do not necessarily correlate with treatment effectiveness, but will 
somehow correlate with other intriguing factors that affect personal perception of 
their physical functioning and social-emotional functioning. Research efforts, and 
eventually treatment efforts, may someday be comprised of a multi-disciplinary 
team focused not only on body, but also on mind and psychosocial support. 
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Appendix A; THE SURVEY INSTRUMENT 
1. Informed Consent p. 138 
2. Survey Instrument p. 139-140 
3. Elect not to participate page p. 141 
4. Request further information page p. 142 
5. Thank you for participating page p.143 
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1. At the bottom of this page you wi l l be asked to indicate that you would either like 
to participate in the survey, NOT participate in the survey, or that you would like 
further information about the survey before continuing. 
1.) I f you choose not to participate you wi l l be directed away from the survey page. 
You may then close your browser. 
2.) I f you wish to obtain more information you wil l be directed to a page that wi l l 
include contact information for the lead researcher of this study, so that you may ask 
your question. 
3.) I f you choose to participate, you wil l be directed to the survey page where you 
wil l then be asked various questions about your SD and how it affects you. When you 
are done with the survey the results wi l l be stored and collected with all other 
participants. 
I f you do not wish to answer a question, you may leave it blank. 
Consent to participate: By checking the agreement to participate checkbox below, I 
am giving my consent to participate in this study. I agree to participate after 
thoroughly reading the above material on this page. I f I have any questions about 
participation in the study, they have already been answered. I also agree that I am 
over 18 years of age. 
CHECK ONLY 1 BOX BELOW 
l I Ves, I have read tne doove information and I choose to participate tn this study. 
V I No, 1 do not want to participate In this study at tnis t n;i>. 
I have questions or reqj 're rncre information aBout this study. 
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1 . What IS your gender? 
f3^*:: 
f 
;2.' What; is-yOur age? • 
^..^What-type of Spasmodic i p | ^ ^ i i ^ S ^ ^ ^ s ^ ; ^ # ) B ^ j i s ? ; 
1 ^ AMuCWfSB . : : i l . ^ : ^ * S - ; : ' i . - - : i . . ; v i ' . . ' «^ .^ .J ] : ;? . ' i \ ; \ - ' ; , -
j i Q | : A d d u « o r SO v ; ; :s! ;** : 
I T J Mtee^ MsSuctorana'Adductor 
I f J Trermsf only 
j i s (• Abductor Sb a«d Tremor 
fteductsr $ 0 ami Tremor 
| M J Abduetar, and Adductor, and Tremor 
' r . •-
©tHer (jsiease specify), .or "don't know* 
Q 
4, How many years ago did you develop SD symptoms? 
5. How many years did it take between the time you started having symptoms and 
the time when you were diagnosed by a medical professional as having SD? 
6. Are you now receiving Botulinum Toxin injections (Botox) for your SD? 
o-
7. Have you had side effects of breathiness from Botox injections that significantly 
lessened the positive effects of the treatment? 
o-
©*> 
8. When you were diagnosed, what severity level were you given in regards to your 
SD? 
OM i i" 
Q_y Severe 
C j Oan't Know 
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9. Have you ever had surgery specifically for your SD diagnosis? 
0v« 
10, We are trying to learn more about how a voice 
day to day activities. 
problem can 
Below, you wil l f ind a list of possible voice 
interfere wi th your 
related problems. 
Please anser all questions based upon what your voice has been like over the past 
two weeks. There are no "r ight" or wrong answers Considering both how severe 
the problem is when you get it, and How frequently it happens, 
below on how "bad" it is (that is, 
please rate each item 
the amount of each probiem that you have). 
the following scale for rating the amount of the problem: 
IssNone, not a problem 
2=A small amount 
3 -A moderate(medium) amount 
4=A lot 
5=Problem is as "bad as it can be 
i . ) I have trouble 
speaking loudly or feeing 
heard in noisy situations, 
2.) I run out of air and 
need to take frequent 
breaths when taking. 
3.) I sometimes <3o not 
know what will come out 
when I begm speaking. 
4.) X am sometimes 
anxious or frustrated 
(because of my voice). 
5.) I sometimes get 
depresses} (because of 
my voice). 
6.) I have trouble usmg 
the telephone (because 
of my voice). 
7.) I have trouble doing 
my job or practicing my 
profession (because of 
my voice). 
8,) I avoid 90109 out 
socially (because of my 
voice). 
9.) I have to repeat 
mysetf to oe understood. 
10.) I have become iess 
outgoing (because of my 
voice). 
6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
«• 
6 
0 
0 
0 
* 
0 
r~ 
O 
O 
O 
O 
6 
Shou:C you become upset a^ter taking psis survey and v,.sh to spe^k to 3 professions- counsels 
239-70?-9127 or by e-ins-A at thofma 
invited you to participate sn Vie study 
-in&hodges. *.:du. You m sy also f i d this contact ^format 
3 
O 
f 
O 
O 
O 
' 
O 
O 
O 
O 
O 
O 
4 
O 
C~ 
O 
O 
f 
O 
4 
O 
C" 
0 
0 
0 
f 
0 
6 
r, p:eas« cail Thomas nofmann dt 
en on the e-tv>a:! you received that 
Use 
5 
O 
C 
O 
O 
O 
O 
O 
O 
O 
0 
O 
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3. You have chosen not to participate in the survey 
THank: you: very much fdr your time andatterrtlijn. 
You may closetKif Wabpagete eh^contafit/Wijthttfsw^ 
hand comer of this: pa$e. Or, youi may aick; ttisnext button and click the close button-or) the following 0ajfe 
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4. Contact Information for the Researchers 
Thanj< you for your time and attention. 
If you have and questions or concerns about this survey, please Contact Thomas Hermann at 239- 707- 9127 or ky; 
e-mail; at thoftfianri<§hodg.es;edu> You should receive a response within 24 hours. Fleas6 dick the-"exit this sttwey''-
(ink at the topi right of the page to close this^ ^ page. Or, click next and then click close oii the following page. 
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5, Thank you! 
Thank you for your time! 
Click the "exit this survey" link at the top right hand side of the page, or the "done" button below to close the 
browser. 
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Appendix B: INTRODUCTORY E-MAIL 
(In Subject Heading) You are invited to participate in the "Spasmodic 
Dysphonia and Quality of Life" survey 
You are invited to participate in a study of how quality of life is affected by 
spasmodic dysphonia (SD). This survey will take approximately 15 minutes to complete. 
The researchers hope to provide information to other researchers and professionals 
about how well people cope with SD and the challenges people with SD face in their 
lives. 
You have received this e-mail through the cooperation of the National Spasmodic 
Dysphonia Association. However, please note that the National Spasmodic Dysphonia 
Association does not endorse or recommend participating in the study. 
Please contact the lead researcher, Tom Hofmann if you have any questions 
about the survey. He can be reached by e-mail at thofmann@hodges.edu or by phone at 
239-707-9127. 
The link below will direct you to the survey. You will be asked to read some 
important information about the study, and then you will be asked to decide if you want 
to proceed. The survey is entirely voluntary. 
Click this link to take the survey: 
ABSD v. ADSD/Quality of Life Issues 14 5 
https://www.survevmonkev.com/s.aspx?sm=h4hDHuhns5PGCPTIBZ3m 2fA 3d 
3d. 
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Appendix C: V-RQOL ALGORITHMS 
V-RQOL General Scoring Algorithm: 
100- [(raw score- # of items in domain or total)/(highest possible raw score-
#ofitems)*100] 
V-RQOL Total Score 
100-[((Raw Score-10)/40)*100] 
V-RQOL Physical Functioning Domain 
100-[((Raw Score-6)/24)*100] 
Raw Score= V-RQOL question scores 1+2+3+6+7+9 
V-RQOL Social-Emotional Domain 
100-[((Raw Score-4)/16)*100] 
Raw Score= V-RQOL question scores 4+5+8+10 
V-RQOL Questions 
We are trying to learn more about how a voice problem can interfere with your 
day to 
day activities. On this paper, you will find a list of possible voice-related 
problems. Please 
answer all questions based upon what your voice has been like over the past 
two weeks. 
There are no "right" or "wrong" answers. 
Considering both how severe the problem is when you get it, and how frequently 
it 
happens, please rate each item below on how "bad" it is (that is, the amount of 
each 
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problem that you have). Use the following scale for rating the amount of the 
problem: 
1 = None, not a problem 
2 = A small amount 
3 = A moderate (medium) problem 
4 = A lot 
5 = Problem is as "bad as it can be" 
1. I have trouble speaking loudly or being heard 
in noisy situations. 
1 2 3 4 5 
2. I run out of air and need to take frequent breaths 
when talking. 
1 2 3 4 5 
3. I sometimes do not know what will come out 
when I begin speaking. 
1 2 3 4 5 
4. I am sometimes anxious or frustrated (because 
of my voice). 
1 2 3 4 5 
5. I sometimes get depressed (because of my voice). 12 3 4 5 
6. I have trouble using the telephone (because of 
my voice). 
1 2 3 4 5 
7. I have trouble doing my job or practicing my 
profession (because of my voice). 
1 2 3 4 5 
8. I avoid going out socially (because of my voice). 12 3 4 5 
9. I have to repeat myself to be understood. 12 3 4 5 
10. I have become less outgoing (because of my voice). 12 3 4 5 
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Appendix D: T-TEST SPSS OUTPUT 
Comparison of ABSD and ADSD by V-RQOL Total Score 
Group Statistics 
SDTYPE 
VRQOLTOT 1.00 
2.00 
N 
41 
86 
Mean 
43.7195 
44.2733 
Std. Deviation 
22.98180 
22.47504 
Std. Error 
Mean 
3.58915 
2.42355 
Independent Samples Test 
VRQOLTOT Equal variances 
assumed 
Equal variances 
not assumed 
Levene's Test for 
Equality of Variances 
F 
.003 
Sig. 
.958 
West for Equality of Means 
t 
-.129 
-.128 
df 
125 
77.236 
Sig. (2-tailed) 
.898 
.899 
Mean 
Difference 
-.55374 
-.55374 
Std. Error 
Difference 
4.29642 
4.33077 
95% Confidence 
Interval of the 
Difference 
Lower 
-9.05690 
-9.17700 
Upper 
7.94941 
8.06951 
Comparison of ABSD and ADSD by V-RQOL Physical Functioning Subscale 
Group Statistics 
SDTYPE 
VRQOLPHY 1.00 
2.00 
N 
41 
86 
Mean 
41.4634 
43.4109 
Std. Deviation 
22.24296 
23.23390 
Std. Error 
Mean 
3.47377 
2.50538 
Independent Samples Test 
VRQOLPHY Equal variances 
assumed 
Equal variances 
not assumed 
Levene's Test for 
Equality of Variances 
F 
.195 
Sig. 
.659 
t-test for Equality of Means 
t 
-.448 
-.455 
df 
125 
81.996 
Sig. (2-tailed) 
.655 
.651 
Mean 
Difference 
-1.94744 
-1.94744 
Std. Error 
Difference 
4.35014 
4.28299 
95% Confidence 
Interval of the 
Difference 
Lower 
-10.55690 
-10.46767 
Upper 
6.66202 
6.57279 
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Comparison of ABSD and ADSD by V-RQOL Social-Emotional Functioning 
Subscale 
Group Statistics 
SDTYPE 
WRQOLSE 1.00 
2.00 
N 
41 
86 
Mean 
47.1037 
45.5669 
Std. Deviation 
27.63806 
24.34559 
Std. Error 
Mean 
4.31634 
2.62525 
Independent Samples Test 
WRQOLSE Equal variances 
assumed 
Equal variances 
not assumed 
Levene's Test for 
Equality of Variances 
F 
.896 
Sig. 
.346 
t 
.318 
.304 
df 
125 
70.526 
t-test for Equality of Means 
Sig. (2-tailed) 
.751 
.762 
Mean 
Difference 
1.53680 
1.53680 
Std. Error 
Difference 
4.82918 
5.05200 
95% Confidence 
Interval of the 
Difference 
Lower 
-8.02074 
-8.53779 
Upper 
11.09434 
11.61138 
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Appendix E: REGRESSION ANALYSIS OUTPUT 
Regression 
[DataSetO] C:\Documents and 
Settings\Administrator\Desktop\Dissertation Data\Regression.sav 
Descriptive Statistics 
VRQOLTOT 
DURATION 
AGE 
SEVERITY 
SIDEEFFECT 
GENDER 
Mean 
44.8551 
11.0290 
51.0435 
2.3623 
1.2609 
1.2609 
Std. Deviation 
23.97488 
8.14026 
12.56446 
.66357 
.44233 
.44233 
N 
69 
69 
69 
69 
69 
69 
Correlations 
Pearson Correlation VRQOLTOT 
DURATION 
AGE 
SEVERITY 
SIDEEFFECT 
GENDER 
Sig. (1-tailed) VRQOLTOT 
DURATION 
AGE 
SEVERITY 
SIDEEFFECT 
GENDER 
N VRQOLTOT 
DURATION 
AGE 
SEVERITY 
SIDEEFFECT 
GENDER 
VRQOLTOT 
1.000 
.212 
.272 
-.052 
.031 
.111 
.040 
.012 
.335 
.399 
.182 
69 
69 
69 
69 
69 
69 
DURATION 
.212 
1.000 
.217 
-.214 
.124 
-.166 
.040 
.036 
.038 
.154 
.087 
69 
69 
69 
69 
69 
69 
AGE 
.272 
.217 
1.000 
.240 
.059 
.265 
.012 
.036 
.024 
.316 
.014 
69 
69 
69 
69 
69 
69 
SEVERITY 
-.052 
-.214 
.240 
1.000 
.024 
.124 
.335 
.038 
.024 
.423 
.155 
69 
69 
69 
69 
69 
69 
SIDEEFFECT 
.031 
.124 
.059 
.024 
1.000 
-.052 
.399 
.154 
.316 
.423 
.335 
69 
69 
69 
69 
69 
69 
GENDER 
.111 
-.166 
.265 
.124 
-.052 
1.000 
.182 
.087 
.014 
.155 
.335 
69 
69 
69 
69 
69 
69 
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Variables Entered/Removed 
Model 
1 
Variables 
Entered 
AGE 
Variables 
Removed Method 
Forward 
(Criterion: 
Probabilit 
y-of-
F-to-enter 
<= .050) 
a- Dependent Variable: VRQOLTOT 
Model Summarty 
Model 
1 
R 
.272a 
R Square 
.074 
Adjusted 
R Square 
.060 
Std. Error of 
the Estimate 
23.24037 
Change Statistics 
R Square 
Change 
.074 
F Change 
5.366 
df1 
1 
df2 
67 
Sig. F Change 
.024 
Di 
Wi 
a. Predictors: (Constant), AGE 
b. Dependent Variable: VRQOLTOT 
ANOVAb 
Model 
1 Regression 
Residual • 
Total 
Sum of 
Squares 
2898.345 
36187.706 
39086.051 
df 
1 
67 
68 
Mean Square 
2898.345 
540.115 
F 
5.366 
Sig. 
,024a 
a- Predictors: (Constant), AGE 
b. Dependent Variable: VRQOLTOT 
Coefficients 
Model 
1 (Constant) 
AGE 
Unstandardized 
Coefficients 
B 
18.332 
.520 
Std. Error 
11.786 
.224 
Standardized 
Coefficients 
Beta 
.272 
t 
1.555 
2.316 
Sig. 
.125 
.024 
5% Confidence Interval for E 
Lower Bound 
-5.193 
.072 
Upper Bound 
41.858 
.967 
a- Dependent Variable: VRQOLTOT 
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Appendix F: T-TEST RESULTS FOR MIXED SD V. ABSD/ADSD ANALYSIS 
All Mixed SD v. Pure ABSD Plus ABSD 
Group Statistics 
ABDMIALL 
VRQOLALL 1.00 
2.00 
N 
157 
73 
Mean 
43.1051 
35.8219 
Std. Deviation 
24.11644 
18.66674 
Std. Error 
Mean 
1.92470 
2.18478 
Independent Samples Test 
VRQOLALL Equal variance: 
assumed 
Equal variance; 
not assumed 
Levene's Test for 
Equality of Variances 
F 
5.582 
Sip. 
.019 
t-test for Equality of Means 
t 
2.281 
2.501 
df 
228 
177.719 
Sig. (2-tailed) 
.023 
.013 
Mean 
Difference 
7.28318 
7.28318 
Std. Error 
Difference 
3.19281 
2.91165 
95% Confid< 
Interval of 
Differenc 
Lower 
.99198 
1.53732 
U 
13.! 
13.1 
Mixed v. Pure ABSD plus ADSD without Botox 
Group Statistics 
ABDMIXNOBO 
VRQOLNOBO 1.00 
2.00 
N 
97 
29 
Mean 
43.7371 
39.6552 
Std. Deviation 
24.81212 
17.40695 
Std. Error 
Mean 
2.51929 
3.23239 
Independent Samples Test 
VRQOLNOBC Equal variances 
assumed 
Equal variances 
not assumed 
Levene's Test for 
Equality of Variances 
F 
5.415 
Sig. 
.022 
t-test for Equality of Means 
t 
.826 
.996 
df 
124 
65.319 
Sig. (2-tailed) 
.410 
.323 
Mean 
Difference 
4.08194 
4.08194 
Std. Error 
Difference 
4.94102 
4.09819 
95% Confidence 
Interval of the 
Difference 
Lower 
-5.69772 
-4.10195 
Upper 
13.86160 
12.26583 
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Mixed v. Pure ABSD plus ADSD with Botox 
Group Statistics 
ABDMIXBO 
VRQOLBO 1.00 
2.00 
N 
103 
41 
Mean 
45.1456 
34.6341 
Std. Deviation 
22.89368 
19.01941 
Std. Error 
Mean 
2.25578 
2.97033 
Independent Samples Test 
VRQOLBC Equal variance 
assumed 
Equal variance 
not assumed 
Levene's Test for 
Equality of Variances 
F 
1.194 
Sig. 
.276 
t-test for Equality of Means 
t 
2.603 
2.818 
df 
142 
87.970 
Sig. (2-tailed) 
.010 
.006 
Mean 
Difference 
10.51148 
10.51148 
Std. Error 
Difference 
4.03884 
3.72980 
95% Confidence 
Interval of the 
Difference 
Lower 
2.52746 
3.09925 
Upper 
18.49551 
17.92372 
ABSD Pure v. ADSD Pure 
Group Statistics 
ABADBOT 
VRQOLBOT 1.00 
2.00 
N 
33 
70 
Mean 
46.0606 
44.7143 
Std. Deviation 
23.42733 
22.79613 
Std. Error 
Mean 
4.07818 
2.72466 
Independent Samples Test 
VRQOLBO' Equal variance 
assumed 
Equal variance 
not assumed 
Levene's Test for 
Equality of Variances 
F 
.083 
Sig. 
.774 
t-test for Equality of Means 
t 
.277 
.275 
df 
101 
61.281 
Sig. (2-tailed) 
.782 
.785 
Mean 
Difference 
1.34632 
1.34632 
Std. Error 
Difference 
4.85627 
4.90462 
95% Confidence 
Interval of the 
Difference 
Lower 
-8.28721 
-8.46016 
Upper 
10.97985 
11.15280 
